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AABSTRACT OF THE DISSERTATION
Abstract of the Dissertation

Human PLCG2 Haploinsufficiency Results in a Novel Immunodeficiency
by
Joshua B. Alinger
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2022
Anthony R. French MD PhD, Chair
NK cells are critical for the recognition and lysis of herpesvirus-infected cells. Patients with NK
cell immunodeficiency may suffer from unusually severe and/or recurrent herpesvirus infections;
however, the genetic cause is frequently unknown. PLCG2 encodes a signaling protein in NK cell
and B cell receptor signaling, in which dominant-negative or gain-of-function mutations may cause
cold urticaria, antibody deficiency, or autoinflammation. However, loss-of-function mutations
and PLCG2 haploinsufficiency have never been reported in human disease. We examined 2
families with autosomal dominant NK cell immunodeficiency with dual high-dimensional
techniques, mass cytometry and whole-exome sequencing, to identify the cause of disease. We
identified two novel heterozygous loss-of-function mutations in PLCG2 that impaired NK cell
function, including calcium flux, granule movement, and target killing. Although expression of
mutant PLCG2 protein in vitro was normal, phosphorylation of both mutants was diminished. In
contrast to PLAID and APLAID, B cell function remained intact. Plcg2+/- mice, as well as
targeted CRISPR knock-in mice, also displayed impaired NK cell function with preserved B cell
function, phenocopying human PLCG2 haploinsufficiency. We report the first known cases
of PLCG2 haploinsufficiency, a clinically and mechanistically distinct syndrome from previously
vii

reported mutations. Therefore, these families represent a novel disease, highlighting a role
for PLCG2 haploinsufficiency in herpesvirus-susceptible patients and expanding the spectrum
of PLCG2-related disease.
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Chapter 1: Natural Killer Cells
Section 1.1 Natural Killer Cells and the Immune Response to Herpesviruses
Herpesviridae is a ubiquitous family of large DNA viruses, eight of which are capable of infecting
humans. The seroprevalence of these viruses in adults exceeds 80-90% and nearly all humans are
infected by one or more members of the family1. Herpesviruses predate both the arrival of adaptive
immunity in jawed vertebrates and the speciation of mammals. Thus, nearly all mammals, as well
as many other organisms, have cospeciated with one or more herpesviruses in the presence of an
adaptive immune system. During this protracted period of coevolution, herpesviruses have evolved
to evade the immune system and latently infect the mammalian host1. Many of these viruses have
evolved specific mechanisms to evade adaptive immunity in particular, such as the active
suppression of endogenous major histocompatibility complex (MHC) expression and the
expression of virally derived MHC-like immunoevasins. Despite this, most immunocompetent
individuals are capable of controlling herpesviruses and rarely develop severe disease.

While adaptive immunity is capable of limiting herpesvirus infections, the active evasion of
antigen presentation suggests the need for other cell types to recognize and suppress viral infection.
This assistance comes in the form of the Natural Killer (NK) cell, designed to detect the
downregulation of class I MHC (MHC-I) and other signs of viral infection (as well as other
pathological conditions such as cellular transformation). Mammals infected with herpesviruses are
capable of recognizing infection via what has been coined the “missing self” hypothesis2. Upon
infection with many types of DNA viruses, MHC-I expression may be reduced, and this reduction
1

is recognized by a reduction in NK cell inhibitory receptor signaling. At baseline, the presence of
MHC-I on the surface of nearly all nucleated cells maintains NK cells in an inhibited state to
prevent autoreactivity. This threshold of activation may be adjusted by activating receptors,
recognizing stress signals or viral proteins, and cytokines secreted by other cell types during
infection. The subsequent activation of NK cells results in several effector functions, including
NK cell proliferation, the degranulation of cytolytic granules to lyse infected target cells, and the
secretion of inflammatory cytokines such as TNFa and IFNγ (figure 1.1).

The study of murine cytomegalovirus (MCMV) in mice that express the Ly49H receptor, an
activating receptor specific for MCMV-encoded m157, has provided an invaluable model for the
study of NK cell activation3,4. The host tropism of MCMV is restricted to mice, however the
pathology and response to MCMV resembles human infection with human cytomegalovirus
(HHV-5). While mice are naturally infected with MCMV via the oral-fecal route, the virus is
introduced either intravenously or intraperitoneally in the laboratory setting and extensive work
has been done to study the immune response to MCMV during infection via these routes. Given
the close relationship and interactions of natural killer cells with other cell types during infection,
it is worth noting the (particularly innate) immunological events occurring during MCMV
infection.

After intraperitoneal injection, MCMV may be detected within the spleen as early as 6 hours after
infection, predominantly within the endothelial or fibroblastic stromal cells of the marginal zone5.
The spleen appears to be the first target of infection and is required for further dissemination, as
splenectomized mice display decreased viral replication within the liver and other sites6. As such,
2

the spleen is commonly examined during MCMV, particularly during the early phases before
dissemination to the liver. By two days post-infection, MCMV may be detected within a variety
of splenocytes including neutrophils, dendritic cells (classical CD8+ XCR1+ dendritic cells), NK
cells and to a minor extent, B and T lymphocytes5. As the first cellular target, stromal cells have
the potential to sense viral infection and replication via Toll-like receptor 3 (TLR3) or cytosolic
sensors which cause subsequent expression of type I interferon (IFN). MCMV encodes at least one
gene capable of inhibiting TLR3 signaling in infected cells, m45, which may limit the importance
of stromal derived type I interferon (IFN-I)7. Nonetheless, IFN-I is detected early in infection,
peaking around 36 hours and remains at this level until 48 hours post-infection, decreasing to
baseline thereafter. The main producers of IFN-I during MCMV are plasmacytoid dendritic cells
(pDC), detecting MCMV infection in a TLR9 dependent manner8. TLR9 recognizes unmethylated
CpG DNA which uncommon in the mammalian genome, likely derived from apoptotic
bodies/exosomes of virally infected cells and/or direct recognition of viral particles themselves8.
Since pDC are rarely directly infected during MCMV infection, they remain shielded from
MCMV-encoded immunoevasins which are expressed within infected cells9. The production of
IFN-I induces the expression of interferon stimulated genes (ISGs) typically via the IFNAR
receptor complex, leading to phosphorylation of the transcription factors STAT1 and STAT2 (as
well as IRF9) with subsequent translocation to the nucleus10. MCMV encodes at least one protein
capable of inhibiting STAT2 signaling, m27, to prevent the induction of ISGs9. Nonetheless, this
pathway appears to be intact during MCMV infection as IFNAR deficient mice remain more
susceptible to MCMV infection than wild-type mice suggesting that IFN-I is still protective during
infection11. In addition to stimulation of virally infected cells, IFN-I also interacts with several
immune cell types, including dendritic cells (inducing maturation and cytokine production) as well
3

as NK cells both indirectly and directly. Indirectly, IFN-I stimulates the expression of IL-15 and
the high affinity IL-15Ra receptor on classical dendritic cells (cDC) which are critical for the transpresentation of IL-15 to NK cells12-14. IL-15 is a critical cytokine for both NK cell
survival/homeostasis as well as proliferation15-17. IL-15 may also synergize with IL-18 to induce
NK proliferation, though IL-18 alone is unable to induce NK proliferation18. Subsequently, IL-15
creates a positive feedback loop within cDC whereby autocrine IL-15 signaling induces CD40 and
allows for CD40-CD40L interactions between cDC and pDC19. This interaction licenses an
increase in the cDC secretion of IL-12, required for NK cell IFNγ expression20. Directly, IFN-I
signaling is also required for NK cell proliferation and maintenance, inhibiting the expression of
the NKG2D ligand and stress signal Rae-1 on NK cells, thus preventing NK cell fratricide during
infection21. IFN-I is also capable of inducing IFNγ expression in NK cells during LCMV infection
in a STAT4 dependent manner22. However, IFN-I may also have negative regulatory effects in this
scheme, as IFN-I is capable of inhibiting IL-12 expression in dendritic cells23. In addition to IL12, IL-18 is also required for optimal NK cell IFNγ secretion24. Both IL-12 and IL-18 are expressed
highly during early infection, peaking at 36 hours and then decreasing thereafter despite increasing
levels of viral titers5. The reason for this decrease in IL-12 and IL-18 is not entirely clear, but likely
stems from a negative regulatory program induced within pDC and CDC, and possibly involves
IFN-I signaling.

As discussed previously, herpesviruses possess several mechanisms to evade T cell immunity by
the active inhibition of antigen presentation. MCMV is no exception to this rule and encodes at
least three proteins that inhibit MHC-I expression at various stages: m04, m06 and m1525.
However, deletion of these genes in MCMV does not alter the kinetics of the T cell response to
4

MCMV. T cell immunity to MCMV involves gamma-delta and natural killer T cells as well as
conventional CD4 and CD8 T cells, though the primary proliferating effector cells are CD8 T
cells5. The uptake of viral antigen in cDC via cross-presentation thus appears sufficient to induce
protective CD8 responses in spite of active downregulation of MHC-I on infected cells. This
downregulation of MHC-I instead allows for NK cell activation, assisted by the activating receptor
Ly49H which recognizes the viral protein m157 in select inbred mouse strains (C57BL/6 but not
BALB/c for example)3,25.

Ly49H plays an important role in the NK cell recognition of MCMV infected cells and is
stochastically expressed on approximately 50% of splenic NK cells26. A paper on the role of Ly49H
and NK cell activation during MCMV, Dokun et al (Nat Immunol 2001), describes a biphasic
process of NK cell activation26. Early in infection, NK cells are stimulated to produce IFNγ and
this process is unbiased in regard to Ly49H- or Ly49H+ NK cells. This likely reflects the large
increase in IL-12 and IL-18 (both required for IFNγ production) that has been described by
numerous groups.

Despite the fact that NK cell-derived IFNγ early in infection is independent of Ly49H, infection
with MCMV lacking the Ly49H ligand m157 (Dm157 MCMV) causes an increase in numerous
cytokines including IFNγ. This is likely a reflection of increased viral titers in the Dm157 MCMV
infection stemming from lack of early control of viral replication. The production of IFNγ peaks
at 36 hours post-infection and returns to baseline by 48 hours. NK cell counts in the spleen decrease
by more than 75% after expression of IFNγ reaching a nadir at 2 days post-infection and then
rapidly expanding thereafter27. This decrease could be attributed to NK migration out of the spleen;
5

however, there is no concurrent increase in NK cell numbers in other tissues, suggesting that NK
cell death may be responsible for this decrease27. Expansion of NK cells from two days postinfection onward results in a Ly49H+ biasing of the NK cell pool, increasing from 50% to 90%
Ly49H+ by 4 days post-infection. Ly49H- cells proliferate little if at all during this phase and
neutralization of Ly49H (either genetically using BxD8 mice or via antibody neutralization)
abrogates this activation26,28. These data imply that Ly49H signaling is sufficient and necessary to
cause NK cell proliferation during MCMV infection. Interestingly, receptor stimulation (including
through Ly49H) is capable of inducing IFNg in vitro even in the absence of IL-12 and IL-18,
however IFNγ is not secreted during this phase indicating that IFNγ secretion is possibly actively
inhibited during this phase29,30.
A later paper supports the importance of Ly49H mediated cytotoxicity but not IFNγ in the spleen
during this specific proliferation phase of infection31. In contrast to Ifng -/- mice, mice deficient in
perforin (required for NK cell and CD8 cytotoxicity) have remarkably increased titers in
comparison to wild-type controls at 5 days post-infection. Interestingly, single deficiencies in IL12, IL-18, IFN-I or Batf3 (resulting in the elimination of IL-15 presenting cDCs) result in viral
control comparable to wild-type mice. However, simultaneous deletion of IL-12 and IFN-I results
in a substantial reduction in granzyme B and perforin levels as well as an increase in viral titers in
the spleen. In this particular study, IFNγ was not required for efficient viral control at this time
point in the spleen, though it was partially required for efficient viral control in the liver suggesting
that there may be organ specific or kinetic differences in the NK response to MCMV. However, a
previous study found that while IFNγ was not required for viral control in the spleen at late time
points (5-6 days), there was an increase in viral titers in the Ifng -/- mice at earlier time points (3
days)32. Overall, these studies suggest that IFNγ is capable of restraining viral growth but given
6

the short kinetics of its secretion and the large increase in Ly49H mediated cytotoxicity later in
infection, it may be partially redundant with Ly49H induced cytotoxicity.
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Figure 1.1 Model of NK Cell Activation
The activation of NK cells results in several effector functions, including NK cell proliferation,
the exocytosis of cytolytic granules to lyse infected target cells, and the secretion of inflammatory
cytokines such as TNFa and IFNγ.
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Section 1.2 NK Cells in Human Disease
Many genetic conditions (reviewed in figure 1.2) affecting granule movement such as ChediakHigashi syndrome (LYST), Griscelli Syndrome (RAB27A), and familial hemophagocytic
lymphohistiocytosis (PRF1, STX11, STXBP2, UNC13D, among others), may affect NK cell
degranulation and function. Forms of Severe Combined Immunodeficiency (SCID) such as JAK3
deficient SCID can also present with both low T and NK cells. However, all of these patients may
also present with T cell deficiency which often underlies the more severe clinical presentation in
these patients. Thus, a variety of immunologic disorders may impact NK cell function; however,
the broader immunodeficiencies in these patients often present a more pressing clinical concern.
Thus, NK cell disorders are defined as immunodeficiencies in which the NK cell deficiency is the
primary immunologic phenotype 33.
To date, only a handful of monogenic NK cell disorders have been described. These examples may
be grouped into two classifications: classical and functional NK cell deficiencies 33. Classical NK
cell deficiencies are defined as genetic disorders in which all or a major subset of NK cells fail to
develop properly, resulting in NK cell cytopenias. This group includes the first published case of
a NK cell deficiency in which the patient presented with overwhelming cytomegalovirus (CMV)
infection due to what was eventually ascribed to GATA2 deficiency, a transcription factor
involved in the maturation of NK cells in the CD56dim NK cell subset34,35. Indeed, this presentation
of herpesvirus susceptibility is common to NK cell disorders as expected by their role in antiviral
defense. The remaining described classical NK cell disorders include mutations in other
transcription factors (IRF8) or DNA repair molecules (MCM4) and may similarly present with
recurrent viral infections. 36,37.

9

By contrast, functional NK cell disorders present with normal circulating levels of NK cells with
diminished function. Clinical NK cell function testing is typically performed using a chromium
based K562 killing assay or a CD107 degranulation assay, both involving the incubation of
primary patient peripheral blood mononuclear cells with a target tumor line, K562, to measure
either target killing or the induction of patient NK cell degranulation38. Examples of functional NK
cell disorders are even more rare, with only one genetic cause (mutations in FCG3A/CD16,
impairing antibody-dependent cellular cytotoxicity) previously described39,40. However, a number
of patients present with herpesvirus susceptibility in the form of either severe or recurrent
infections with reduced clinical NK cell function who do not receive genetic diagnoses.
NK cells have also been implicated in the development or progression of a number of autoimmune
or autoinflammatory syndromes including multiple sclerosis, rheumatoid arthritis, systemic lupus
erythematosus (SLE), autoimmune thyroid disease, psoriasis, systemic juvenile idiopathic arthritis
(sJIA), and juvenile dermatomyositis (JDM)41-52. Many of these studies offer only correlative
evidence in the form of decreased NK cell numbers or function in the context of active disease;
however, NK cells are known to play an important role in immunoregulation either by the secretion
of immunomodulatory cytokines or by the direct targeting of activated T cells 53-55. NK cells also
regulate humoral immunity through the negative regulation of T follicular helper cells, an
overabundance of which has been implicated in the development of autoantibodies and
autoimmune disease 56,57. Thus, in addition to the expected viral immunodeficiency in patients with
NK cell disorders, a variety of other phenotypes, including but not limited to autoimmunity and
immunodysregulation, may be present in these patients. Nonetheless, a more thorough
investigation of the role of NK cells in autoimmunity is needed to understand the mechanism
and/or role of NK cell dysfunction in these diseases.
10

Figure 1.2 Human Disorders Impacting NK Cell Function
NK cell function and development can be impacted by a number of genetic conditions, however
many conditions (shown in bold black) affect other cell types such as CD8 T cells. Only four
genetic causes of specific NK cell deficiency (shown in green bold) have been previously
described.
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Section 1.3 Human NK Cell Receptors and Signaling
Human NK cells can be differentiated into two main circulating classes, the CD56Bright and CD56Dim
NK cell subsets58-60. CD56Bright NK cells are generally thought to be cytokine-producing and
immunomodulatory; however, with proper cytokine stimulation can be cytolytic61. Nonetheless,
CD56Dim NK cells are considered the major cytotoxic NK cell subset in human blood and are the
only subset capable of CD16-mediated antibody-dependent cellular cytotoxicity (ADCC).
Human NK cells use a variety of germline-encoded receptors to recognize viral and/or stress
ligands present on the surface of cells. including the Natural Cytotoxicity Receptors (NCR)
NKp30, NKp44, and NKp46, as well as NKG2C, NKG2D, the ADCC receptor CD16 and certain
ITIM-deficient KIR receptors which are capable of triggering cytotoxicity62. NK cells also express
costimulatory receptors that may also be found on T cells including NKp80, DNAM-1, 2B4, and
NTA-B. The vast majority of NK cell receptors signal through either CD3ζ or DAP12; however,
exceptions to this exist that signal through DAP10 or FcεRIγ (NKG2D and KIR2DL4,
respectively). While certain details about costimulatory receptor signaling in NK cells remain to
be solved, their signaling through SAP, hemITAM, or ITT domains remains largely conserved as
it functions in T cells. NK cell receptor expression, ligands, and signaling mechanisms are
reviewed with references in table 1.1.
NK cell receptor signaling through DAP12, FcεRIγ, and CD3ζ (representing the majority of NK
cell receptors) proceeds in an analogous fashion to T cell receptor signaling63. The recruitment of
these ITAM-bearing adaptor molecules and an aspartic acid residue in their hydrophobic tail to
NK receptors is facilitated by a charged, basic residue within the cytoplasmic domain of each NK
receptor64,65. The strength of the interaction between these residues dictates receptor:adaptor
12

specificity, though few examples are absolute. Upon engagement between these residues, Src
family members such as Lck lead to the tyrosine phosphorylation of several substrates including
Grb2, PI3K and Syk family members such as ZAP-70. The activation of Syk family members
through tyrosine phosphorylation in turn leads to another round of substrate phosphorylation,
including poly-phosphorylation of LAT. LAT is a scaffold protein through which many members
of this signaling cascade may dock to phosphotyrosine residues with SH2 domains, including the
Grb2-SLP76 complex, Vav, and Phospholipase-Cg (PLCg)66. The Vav-Rac pathway is
subsequently able to activate the MAP Kinase pathway via MEK and ERK to support cytotoxicity
and cytokine secretion67. Meanwhile, the recruitment of PLCg to LAT enables recruitment of its
respective kinase, Itk (a member of the Tec family of kinases) to allow for phosphorylation and
catalytic activation of PLCg68,69. The catalysis of PIP2 into IP3 and DAG via PLCg is a key
triggering event in NK receptor activation as IP3-induced calcium flux is critical for the
mobilization of cytolytic granules, while localized DAG formation serves as a homing target for
granule movement70-72. The regulation and activation of PLCg is reviewed in Chapter 2. At many
steps of this process, the counter-regulation of this cascade through inhibitory receptors is achieved
through KIR activated SHIP, SHP-1, and SHP-2 phosphatases that may dephosphorylate a number
of substrates, disabling the formation of the signalosome73. Figure 1.3 summarizes this signaling
cascade.
NKG2D is also a major NK cell receptor expressed on human NK cells that differs significantly
in its activation from the pathway described above. In using DAP10 in lieu of other adaptor
molecules, DAP10 activation occurs independent of Syk kinases and relies specifically on PLCG2,
contrasting the promiscuity that DAP12, FcεRIγ, and CD3ζ share in their use of either PLCG1 or
13

PLCG274. While DAP10 also requires SLP-76 and Grb2, Vav1 instead of Vav2/3 is preferentially
used in NKG2D/DAP10 signaling67. Intriguingly, while most NK receptors are capable of
activating calcium flux alone, NKG2D requires either costimulation or crosslinking with another
NK cell receptor for productive activation, a process that depends in part on the synergistic
activation of PLCG275,76. NKG2D crosslinking alone is also insufficient to trigger cytokine
secretion in contrast to certain other NK cell receptors such as CD1676. Thus, NKG2D/DAP10
signaling represents a unique departure from the NK signaling paradigm presented above.
Nonetheless, the importance of NKG2D is underscored by its critical role in various models of
malignancy investigated using NKG2D knockout mice77.

14

Figure 1.3 NK Cell Signaling through DAP12
Briefly, the association of activating receptors and DAP12 lead to the recruitment of Src, Syk, and the polyphosphorylation of LAT. Phosphotyrosine residues on LAT serve to scaffold a number of downstream
signaling molecules including VAV, SLP-76 and PLCG-2 (shown in simplified domain structure in blue).
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Table 1.1: Human NK Cell Receptors, Ligands, and Signaling
Receptor

Type

Ligand

Adaptor

Expression

NKp80
DNAM-1
2B4

Coreceptor78
Coreceptor81
Coreceptor84

hemITAM80
ITT-1 Motif83
SAP88,89

Most circulating78
Most circulating83
Most circulating90

NTB-A

Coreceptor91
Natural Cytotoxicity Receptor95,96

SAP93
EAT-294
CD3ζ98

Most circulating92

NKp30
NKp44

Natural Cytotoxicity Receptor 100

DAP12103

Activated
NK Cells104

NKp46

Natural Cytotoxicity Receptor

AICL79
Nectin-2, PVR82
CD4885,86
Viral HA87
NTB-A92
Viral HA87
B7-H697,
BAG6, BAT398
pfEMP199
PCNA101
21spe-MLL5,
HSPG,
NID1, PDGF-DD 102
Properdin107
Viral HA108
PfEMP199
MIC-A109,
MIC-B110, ULPB111
HLA-E113,114

DAP12103

Most
circulating105,106

DAP10112

Most circulating112

DAP12115

Small populations,
CMV seropositive+

105,106

NKG2D

Activating Receptor

NKG2C

Activating Receptor (complex with
CD94)

Most circulating96

116

CD16

117-119

ADCC Receptor

118

120

IgG

CD3ζ

CD56Dim>CD56Bright5
8

KIR2DS1

HLA-specific NK Receptors

HLA-C2

121

KIR2DS4

HLA-Cw4122
HLA-A*11123
Bacterial RecA124

KIR3DS1

HIV125, HLABw4126
HCV, HLA-F125
HLA-G128

KIR2DL4

HLA-specific NK Receptor

16

115

DAP12

Stochastic127

FcεRIγ129

Most circulating 128

Chapter 2 Phospholipase-Cg
Section 2.1 Phospholipase-C Signaling
Humans express thirteen isozymes of phospholipase-C enzymes grouped into β, -γ, -δ, -ε, -η, and
-ζ families depending on sequence, domain structure, and regulation130-139. This diverse family of
enzymes links a variety of cell surface receptors to downstream cellular functions, united by their
common catalytic function of converting phosphatidylinositol 4,5-bisphosphate (PIP2) at the cell
membrane into 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)130,140. The canonical cascade
of phospholipase-C activation results in the release of endoplasmic reticulum stored calcium as
well as the influx of extracellular calcium through calcium release activated channels (CRAC)
such as ORA1 and ORA2141. The cell type and signaling context determines the consequence of
this activation; however, the role of calcium as a second messenger is well established in a wide
number of processes ranging from the stimulation of cell growth and proliferation to cellular
motility to lymphocyte activation142.

Nearly all isozymes in the phospholipase-C family contain a common set of domains including a
1) N-terminal Plecktstrin homology (PH) domain functioning to bind PIP2, PIP3 or Rac
GTPases143-147, 2) EF-hand domains enabling catalysis148, membrane targeting149 or G-protein
dependent signaling150, and 3) a calcium-binding C2 domain critical for the structural stabilization
of the X/Y boxes of the catalytic triose phosphate isomerase (TIM) domain144,151,152. Beyond this
common core of catalytically critical domains, each isozyme within the phospholipase-C family
contains a unique set of regulatory domains that enables their specific activities.
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Phospholipase-C-gamma (PLCg) isozymes are unique within the family for their additional split
PH domain, tandem Src homology 2 (SH2) domains and a Src homology 3 (SH3) domain that
allows for interaction with specific receptor tyrosine kinases and scaffolding molecules. The split
PH domain enables phosphorylation-independent Rac GTPase activation of PLCg (specifically
PLCG2 more so than PLCG1)153-155. The two SH2 domains of PLCg consist of a N-terminal SH2
(nSH2), enabling binding to the lymphocyte scaffold protein LAT69,156,157 and an autoinhibitory
C-terminal SH2 (cSH2)158 which may also enable protein-protein contacts critical for
signalosome assembly159. Meanwhile, the SH3 domain allows for interaction of PLCg with SLP76, completing the T and NK cell receptor signalosome composed of PLCg, LAT, SLP-76 and the
SLP-76 adaptor Gads160.

The association of PLCg with either receptor tyrosine kinases or with signalosome-recruited Tec
kinases (such as Itk or Btk) results in the tyrosine phosphorylation of PLCg kinases at multiple
sites161,162. These sites in PLCG1 include Tyr771, Tyr775, Tyr783, and Tyr1254. The interaction
of Tyr783 is critical for rearrangement of the autoinhibitory cSH2 domain and subsequent
association of the X and Y catalytic domains161,163,164. The analogous site in PLCG2, Tyr759, is
likely similarly regulated, although phosphorylation of both Tyr753 and Tyr759 are required for
optimal PLCG2 signaling in B cells165.

While PLCG1 is ubiquitously expressed, PLCG2 is restricted to the hematopoietic lineage166. T
cell receptor (TCR) signaling appears largely unrestricted in its use of either PLCG1 or PLCG2
for signal transduction, although PLCG1 is traditionally thought of as the key molecule in TCR
activation. Contrastingly, B cell receptor signaling has long been known to be specifically
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dependent upon PLCG2 signaling167,168. In contrast to the nSH2 and SH3 domains binding to LAT
and SLP-76, respectively, in TCR signaling, B cell receptor (BCR) signaling requires the cSH2
and C2 domain interfaces of PLCG2 to associate with BLNK and the B cell signalosome168. Thus,
unique features of these domains in PLCG2 versus PLCG1 may engender this process to the former
isozyme. Moreover, unlike PLCG1, PLCG2 is uniquely able to engage Rac through the split PH
domain and this interaction is required for optimal BCR signal transduction168,169.

As described in chapter 1, PLCG2 is also critical to NK cell function; however, the use of PLCG1
or PLCG2 in NK cells is most likely NK cell receptor dependent. Canonical NK receptors such as
NKp46 use a signaling cascade closely related to TCR signaling and likely are unrestricted in their
use of either isozyme. Certain receptors such as NKG2D use a Vav2/3-Rac-mediated signal
transduction that, similar to BCR signaling, may require the split PH domains of PLCG2 to
associate and optimally activate catalytic function67. However, a clear mechanism for why NK cell
function is more dependent upon PLCG2 than PLCG1 is not clear.

PLCG2 expression is not solely restricted to B, T, or NK cells. A number of other cell types use
and require PLCG2 for function. Macrophages require PLCG2 for trafficking of Toll-like receptor
4 (TLR4) to the endosomes and optimal interferon regulatory factor 3 (IRF3) activation to sense
virally derived nucleic acids170. PLCG2 is also required downstream of M-CSF receptor signaling
for optimal monocyte differentiation, as well as downstream of IL-3 and GM-CSF signaling in
hematopoietic development171,172. Platelet adhesion downstream of glycoprotein Ib (GPIb)-von
Willebrand factor complex signaling is also dependent upon PLCG2173. RANKL-induced
activation of osteoclasts is also specifically dependent on PLCG2, and this restriction of RANKL
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signaling to PLCG2 also applies to RANKL regulation of lymphatic architecture174, demonstrating
a wide range of functions uniquely dependent on this gene.

A schematic representation and a summary of the known domain structures and functions of
PLCG2 are included in figure 2.1 and table 2.1, respectively.

20

PH

P

nSH2

cSH2

SH3

H

Y

C2

7
11
6

4
10 4
59

10

91
0
93
0

82
9
84
0

4
76
6

74

63
645
1

9
52
4
52
7

7

X

47

45

2

9

EF

31

30

13
8
16
0

13
1

1265

Figure 2.1 Phospholipase-C-g2 Domain Structure
The human PLCG2 sequence was analyzed using IntroPro protein sequence analysis and
classification software160. Abbreviations: PH, Plecktstrin homology. SpPH, split Plecktstrin
homology. SH2, Src homology.
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Table 2.1 Phospholipase-Cg2 Interpro-Predicted Domain Structure
PLCG2 Domain
PH Domain

Amino Acid Residues
13-138

EF Hand

160-309

TIM, X-Box
N-terminal SpPH

312-457
479-524

N-terminal SH2

527 - 635

C-terminal cSH2

641 - 744

SH3
C-terminal SpPH
TIM, Y-Box
C2 Domain

766 - 829
840-910
930 - 1,044
1,059 - 1,167

Function
PIP2, PIP3 or Rac GTPase
binding143-147
Supports catalytic domain
structure148, membrane
targeting149 and G-protein
dependent signaling150
PIP2 Catalysis
Phosphorylation-independent
Rac GTPase activation of
PLCg
Binding to lymphocyte
LAT69,156,157
Autoinhibitory158 B cell
signalosome assembly159.
SLP-76 binding175
Same as N-terminal SpPH
PIP2 Catalysis
Structural stabilization of the
X/Y boxes of the catalytic
domain144,151,152

Table 2.1 Legend
The human PLCG2 sequence was analyzed using IntroPro protein sequence analysis and
classification software160. Abbreviations: PH, Plecktstrin homology. TIM, triose phosphate
isomerase. SpPH, split Plecktstrin homology. SH2, Src homology.
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Section 2.2 Mouse Models of Phospholipase-C
Although mice homozygous for Plcg1 are embryonically lethal, dying at embryonic day 9176,
Plcg2 knockout mice develop normally and serve as an important tool for the study of Plcg2 in
immune function. These mice were first reported to have defects in B cell development and
function177; however, subsequent studies also described defects in NK cell cytotoxicity178,179,
lymphatic development174, male fertility180, and osteoclastogenesis174. Consistent with the role of
Plcg2 in signaling, mice deficient in Plcg2 have decreased calcium flux after BCR stimulation
leading to a reduction in B cell development and function, impairing the humoral response. Two
groups subsequently described the role of Plcg2 in NK cells, demonstrating the absolute
requirement for Plcg2 in murine NK cells. Colonna et al. described that murine NK cells express
trivial amounts of Plcg1178, and NK cells deficient for Plcg2 thus have reductions in cytotoxicity,
activating receptor induced cytokine secretion, and susceptibility to MCMV in vivo. Colucci et al.
later mechanistically attributed this to a defect in NK cell activating receptor calcium flux which
led to decreased malignant and virally infected cell clearance, but did not affect either NK cell
development or NK cell-target conjugate formation179.
Several N-ethyl-N-nitrosourea (ENU) mutagenesis studies have produced mice with spontaneous
mutations in Plcg2 that serve as an interesting study in the role of this enzyme in immune function.
The first described model was the Ali5 mouse, a mouse heterozygous142 for a gain-of-function
mutation in Plcg2 at D993G181. This gain-of-function mutation led to severe spontaneous
inflammation and autoimmunity in this model. Somewhat paradoxically, these mice were later
found to be resistant to an experimental model of Helicobacter-induced mucosa-associated
lymphoid tissue (MALT) lymphoma, possibly as a result of increased regulatory T cell (Treg)
23

numbers and a decrease in proinflammatory cytokine after infection, compared to wild-type
controls182. A related phenotype is seen in the Ali14 mouse model, which are heterozygous for a
distinct gain-of-function mutation at Y495C of the split PH domain of Plcg2, and exhibit a wide
range of phenotypes from hypergammaglobulinemia to infertility142. Contrastingly, Queen mice
possess a heterozygous mutation at I346R of the X-box catalytic domain and have been described
as having defects in B cells function, presumably as a result of a loss-of-function mutation at that
position183.

Section 2.3 PLCG2 in Human Disease
Mutations of PLCG2 in humans have been previously reported as well and are summarized in table
2.2. Somatic mutations of PLCG2 have been reported in chronic lymphocytic leukemia treated
with the Btk kinase inhibitor Ibrutinib184. The canonical Ibrutinib PLCG2 escape mutant, R665W,
confers a Btk-independent gain-of-function mutation; however, other mutations have been
reported at P664, P665, S707, L845, D993, D140 and M1141185-187. Indeed, nearly 80% of patients
with progressive CLL have mutations in PLCG2, demonstrating the importance of PLCG2 in Btk
signaling and B cell development185,187.
The first germline mutations of PLCG2 was reported in 2012 by Milner et al. in a cohort of 27
patients with fully penetrant cold urticaria, as well as varying degrees of recurrent sinopulmonary
infections, antibody deficiency, autoimmune disease, and allergic disease188-190. In these patients
with PLAID (PLCG2-associated antibody deficiency and immune dysregulation), deletions of
either exon 19 or exons 20-22 result in the deletion of portions of the autoinhibitory C-terminal
SH2 (cSH2) domain and SH3 domain. Intriguingly, while these mutations resulted in reduced
calcium flux at physiological temperatures, cold temperatures result in increased mast cell
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degranulation due to a temperature sensitive gain-of-function mechanism with these deletions.
Though this gain-of-function is likely due to the loss or dysfunction of the autoinhibitory cSH2
domain, the loss-of-function phenotype was described in a later study to be the result of a deletion
of an interaction surface on the cSH2 domain critical for B cell signalosome assembly, resulting
in dominant-negative inhibition of B cell signaling159.
The second inherited syndrome involving PLCG2 was reported later the same year, this time
involving a dominantly inherited autoinflammatory disease involving blistering skin lesions,
granulomatous inflammation, lung disease, ocular inflammation, arthralgias, enterocolitis, and
mild antibody deficiency191. Whole exome sequencing identified a heterozygous point mutation at
a highly conserved site, S707Y in the cSH2 domain that, unlike PLAID, conferred gain-of-function
activity even at physiologic temperatures. This gain-of-function activity was hypothesized then to
lead to increased lymphocyte and neutrophil activation resulting in non-specific autoinflammation
and the syndrome was coined APLAID (autoinflammation and PLCG2-associated antibody
deficiency and immune dysregulation). The mild immunodeficiency, which presented in the form
of decreased circulating memory B cells and immunoglobulins, is hypothesized to be the result of
substrate-depletion and tachyphylaxis, though this mechanism has not been experimentally tested.
An additional patient with inflammatory lesions, uveitis, interstitial lung disease and IBD was also
later described with a novel mutation in PLCG2 at L848P192. Recently, other mutations in patients
with APLAID-like disease have been reported at R730K, N798S, and M1141L, demonstrating that
mutations in other domains may also result in APLAID (personal communication with Ivona
Aksentijevich).
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Rare variants in PLCG2 have also been implicated as a protective variant in Alzheimer’s disease.
Along with the microglial receptor TREM2, patients with a mutation at P522R in PLCG2 are
protected from Alzheimer’s with an odds-ratio of 0.68193. Although this mutation lies within an
interdomain region between the split-PH and nSH2 domain, functional characterization of this
mutant show a weak hypermorphic phenotype, possibly leading to increased microglial activation
and thus potential clearance of amyloid plaques194. However, the exact mechanism of this
protection has not been thoroughly explored and thus remains to be seen. Known mutations in
both mouse and human PLCG2 are summarized in table 2.2.
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Table 2.2 Reported Mutations in PLCγ2
Species
Mouse

Human

Mutation
D993G181

Name
Ali5

Type
Germline

Domain
X-box

Mechanism
GOF

Y495C142

Ali14

Germline

spPH

GOF

I346R183

Queen

Germline

TIMBarrel

Unknown

Somatic

cSH2
cSH2
cSH2
cSH2
spPH
Y-Box

Unknown

Germline

cSH2

LOF &
GOF

APLAID Germline

cSH2

GOF

P664S186
P665W186
S707Y186
DS707-A708186
L845F186,187
D993Y185
DW646-R685188

PLAID

DY686-W806188

S707Y191
L848P192

P522R

spPH

Germline

nSH2

GOF

Phenotype
Autoinflammation
and autoimmunity,
MALT lymphoma
resistance182
Inflammatory
arthritis and
infertility142
Reduced Tindependent IgM
response195
Ibrutinib resistance
in Chronic
Lymphocytic
Leukemia

Cold urticaria,
antibody
deficiency, allergic
disease,
autoimmunity
Granulomatous
inflammation,
inflammatory
bowel disease,
uveitis, arthralgias,
antibody
deficiency
Protective variant
in Alzheimer’s
disease194

Table 2.2 Legend
Previously reported mutations in mouse and human PLCγ2 are summarized. Abbreviations: GOF,
Gain-of-function. LOF, Loss-of-function. PLAID, PLCγ2-associated antibody deficiency and
immune dysregulation. APLAID, autoinflammation and PLCγ2-associated antibody deficiency
and immune dysregulation. spPH, split Pleckstrin homology domain. cSH2, C-terminal Src
homology domain. nSH2, N-terminal Src homology domain.
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Abstract
Although most individuals effectively control herpesvirus infections, some suffer from unusually
severe and/or recurrent infections requiring anti-viral prophylaxis. A subset of these patients
possess defects in NK cells, innate lymphocytes which recognize and lyse herpesvirus-infected
cells; however, the genetic etiology is rarely diagnosed. PLCG2 encodes a signaling protein in NK
cell and B cell receptor-mediated signaling, among other cell types. Dominant-negative or gainof-function mutations in PLCG2 cause cold urticaria, antibody deficiency, or autoinflammation.
However, loss-of-function mutations and PLCG2 haploinsufficiency have never been reported in
human disease. Using mass cytometry and whole-exome sequencing, we identified novel
heterozygous mutations in PLCG2 in two families with severe and/or recurrent herpesvirus
infections. In vitro studies demonstrated that these mutations were loss-of-function and resulted
in impaired NK calcium flux, granule movement, and cytotoxicity. In contrast to dominantnegative or gain-of-function PLCG2 mutations, B cell function remained intact. Plcg2+/- mice, as
well as targeted CRISPR knock-in mice, also displayed impaired NK cell function with preserved
B cell function, phenocopying human PLCG2 haploinsufficiency. We report the first known cases
of PLCG2 haploinsufficiency, a clinically and mechanistically distinct syndrome from previously
reported mutations. Therefore, these families represent a novel disease, highlighting a role for
PLCG2 haploinsufficiency in herpesvirus-susceptible patients and expanding the spectrum of
PLCG2-related disease.
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Section 3.1 Introduction
Nearly all individuals will encounter herpesviruses such as herpes simplex virus 1 (HSV1) or
cytomegalovirus (CMV) in their lifetime196. Although most will present with only limited
recurrences, some patients will continue to have unusually severe and/or recurrent herpesvirus
infections197. A subset of these patients possess defects in natural killer (NK) cells, innate
lymphocytes which recognize and lyse herpesvirus-infected cells2,34,198. NK cell deficiency (NKD)
can result from either aberrant NK cell development (classical NKD) or reduced NK cell function
(functional NKD), typically evaluated by measuring NK cell killing and CD107 degranulation
after incubation with K562 target cells198. Despite these diagnostic tools, there is minimal
understanding of the genetics underlying functional NKD, and most patients do not receive a
definitive diagnosis. Herein, we present a novel syndrome of functional NK cell
immunodeficiency caused by heterozygous loss-of-function mutations in PLCG2.

NK cells recognize herpesvirus-infected cells using an array of germline-encoded activating
receptors, such as CD16, NKG2D and 2B4199. Many activating receptors signal via a pathway
involving Src and Syk kinases, LAT, and PLCG2-induced secondary messengers199. PLCG2
(encoding phospholipase-C-g2) is recruited to LAT, phosphorylated, and subsequently cleaves
PIP2 into IP3 and DAG. This critical process initiates an increase in cytosolic calcium via both
extracellular influx as well the release of intracellular calcium stores, leading to the polarized
mobilization of cytotoxic granules towards the target cell72. PLCG2 is expressed in hematopoietic
cells and is related to the ubiquitously-expressed PLCG1. While PLCG1 is sufficient for many
signaling pathways including mitogen and TCR signaling, PLCG2 is uniquely necessary for NK
cell and B cell signaling, as demonstrated by their profound disruption in Plcg2-/- mice178,179,200.
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Although PLCG2 is traditionally thought of as a NK- and B- cell signaling molecule, it also plays
a role in several other cell types including platelets173, neutrophils201, monocytes, and
macrophages171.

Mutations in PLCG2 have been previously reported in a separate domain (the C-terminal SH2
domain, cSH2), causing the syndromes PLAID and APLAID. PLAID is caused by exonic
deletions compromising the cSH2 domain and results in gain-of-function at sub-physiologic
temperatures159,188,189. At normal temperatures, PLAID acts in a dominant-negative manner to
dysregulate immune signaling. While NK cell degranulation is reduced in PLAID, B cell and mast
cell dysregulation underlie the predominant clinical phenotypes in these patients, including
antibody deficiency and cold urticaria159,188,189. APLAID is caused by a constitutive gain-offunction mutation (S707Y) and results in autoinflammation and B cell immunodeficiency (perhaps
as a result of substrate depletion)191. Herein, we demonstrate that heterozygous loss-of-function
mutations in PLCG2 result in a clinical phenotype distinct from PLAID and APLAID, extending
the spectrum of disease seen with human mutations in PLCG2.

Section 3.2 Materials, Methods and Statistics
Data Availability Statement
With the exception of whole-exome sequencing data, the distribution of which may compromise
research participant privacy and/or consent, the data that support the findings of this study are
available from the corresponding author upon reasonable request.
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Patients and Sample Collection
All human samples were obtained using written informed donor consent and were used with the
approval of either the Washington University School of Medicine Institutional Review Board or
the Baylor College of Medicine Institutional Review Board for the Protection of Human Subjects.
All samples were obtained in compliance with the Declaration of Helsinki. Peripheral blood
mononuclear cells (PBMC) were isolated by density centrifugation over Ficoll-Paque according
to manufacturer’s instructions prior to liquid nitrogen cryopreservation in fetal bovine serum and
DMSO.

Animal Studies
Plcg2 mice were generated by Jim Ihle (St. Jude Children’s Research Hospital)200 and backcrossed
onto a B/6 background for 10 generations by Marco Colonna (Washington University)178. Mice
were maintained under specific pathogen–free conditions and used between 8 and 14 weeks of
age. Mouse experiments were performed in both male and female mice with equivalent results.
All experiments were approved and conducted in accordance with Washington University Animal
Care and Use Committee guidelines for animal care and use.

Exome Sequencing
For kindred A, exome sequencing was performed as previously described202. Briefly, genomic
DNA was extracted from whole blood or saliva and coding regions enriched using SureSelect All
Exon (Agilent Technologies) followed by next-generation sequencing (Illumina) at St. Louis
Children’s Hospital through the Genome Technology Access Center at Washington University.
For kindred B, whole exome sequencing was performed on genomic DNA by Baylor Genetics as
32

previously described203,204. After quality control, alignment and variant calling, exome data was
analyzed using institution-specific pipelines to identify potential variants. Medium or high impact
variants (i.e. non-synonymous changes, early stops, frameshifts and splice site mutations) with
minor allele frequencies less than 0.01 in ExAC205 were prioritized and potential variants were
cross-referenced between kindreds. Both kindreds were negative for variants in known genes
associated with immunodeficiency and immunodysregulation206, including HLH mutations207 and
NK cell associated mutations in MCM4, GATA2, IRF8, FCGR3A (CD16) and KLRC2
(NKG2C)35-37,198,208.

Transfection Experiments
293T cells (ATCC CRL-3216) were cultured in Dulbecco’s modified eagle media supplemented
with 10% fetal bovine serum. Cells were transfected with a mammalian expression vector driven
under MND promoter containing N-terminal FLAG tagged PLCG2 (WT or relevant mutation)
using Lipofectamine LTX (Invitrogen) and incubated for 24 hours. Cells were then stimulated with
100 M pervanadate and either lysed with RIPA buffer or fixed using 1.6% formaldehyde 15
minutes post-stimulation. Western blot analysis of protein expression was performed using antiFLAG (Sigma, clone M2) or Actin (Santa Cruz Biotechnology, clone C-11). PLCG2
phosphorylation was analyzed by flow cytometry as described below using PE anti-PLCG2 Y759
(clone K86-689.37, BD).

NK Cell Cytotoxicity Assays
PBMCs isolated as described above were thawed and allowed to rest for 1 hour in Roswell Park
Memorial Institute (RPMI) media supplemented with 20% FBS, pyruvate, non-essential amino
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acids, glutamine and HEPES. Cells were then seeded into 96 well U-bottom plates along with
CellTrace Violet (Invitrogen) labeled K562 (ATCC, CCL-243) tumor target cells at a PBMC:K562
ratio of 50:1. After incubation for 4 hours, 7-AAD (BD) was added and target cell death was
quantified using flow cytometry. Mouse NK cell assays were performed similarly except that NK
cells were isolated from spleen using EasySep Mouse NK Cell Enrichment (Stem Cell
Technologies) and then mixed with CellTrace Violet labeled YAC-1 (ATCC, TIB-160) or RMAS cells (kind gift from Wayne Yokoyama).

Microscopy
For analysis of NK-target cell conjugates, fixed cell confocal microscopy was performed using
patient NK cells and K562 erythroblast target cells. 3x106 PBMC from patient or heathy donor
were incubated with K562 target cells for 45 minutes then fixed, permeabilized and stained with
anti-perforin Alexa Fluor 488 (clone dg9), anti-tubulin biotin followed by Pacific Blue conjugated
streptavidin, and phalloidin Alexa Fluor 568. Images were acquired on a Zeiss AxioPlanII with a
Yokogawa CSU-10spinning disk and Hamamatsu ORCA-ER camera. Excitation lasers (405 nm,
488 nm, 561 nm, 647 nm) were merged through a Spectral Applied Research laser merge. Images
were taken throughout the volume of cell conjugates using 0.5µm steps. Acquisition and analysis
were performed using Velocity software (PerkinElmer). For measurement of actin accumulation,
analysis was performed as described previously209. Briefly, area and intensity of F-actin at the
immunological synapse were measured for a defined area. Cortical F-actin intensity from both NK
and target cells was subtracted from this measurement to generate a quantitative measure of
specifically accumulated actin at the synapse. For MTOC polarization, MTOC were defined as the
highest intensity staining of a-tubulin and the distance between this and the center of the
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immunological synapse was measured for 30 conjugates each from patient and healthy donor.
Granule convergence was analyzed as previously described210. Distance between individual lytic
granules and the MTOC were measured and the mean of these was calculated for each cell.

Mass Cytometry
Mass cytometry is a high-dimensional single cell analysis technique based on flow cytometry but
differs in its use of metal tagged antibodies in lieu of fluorophores. Procedure performed as
described previously211,212 and acquisition was performed using a CyTOF instrument (Fluidigm).
Data was analyzed and viSNE was performed using Cytobank213,214. Briefly, for the panel in table
3.2, PBMCs were isolated, thawed and rested as detailed above. Cells were stained with cisplatin
to track cell viability. Between 1x106 and 3x106 PBMCs per time point were stained with metal
conjugated extracellular antibodies (Fluidigm), seeded in 96-well U bottom plates and stimulated
with either a cocktail of A) 500U/mL IFNa (Peprotech), 500ng/mL LPS (Invivogen), 50ng/mL
IL-12 (Peprotech), and 500U/mL IL-2 (Proleukin), and CD16/CD3/IgM crosslinking (using
surface staining antibodies followed by anti-mouse IgG, Biolegend) for 0, 3 and 15 minutes. Cells
were then fixed in 1.6% formaldehyde and permeabilized in 100% methanol. After washes,
intracellular staining was performed before DNA staining using Cell-ID Intercalator-Ir (Fluidigm).
For the panel in table 3.3, cells were stained with cisplatin to track cell viability. Between 1x106
and 3x106 PBMCs were unstimulated or mixed with 1:1 K562 cells and 500U/mL IL-2 (Proleukin)
in the presence of GolgiStop (BD), GolgiPlug (BD) and metal-conjugated CD107 antibody
(Fluidigm). Cells were then stained with conjugated extracellular antibodies (Fluidigm) or
antibodies conjugated to the desired metal using Maxpar Antibody Labeling Kit (Fluidigm). Cells
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were fixed in CytoFix/CytoPerm (BD), washed in Perm Buffer (eBioscience) and stained with
intracellular antibodies before DNA staining using Cell-ID Intercalator-Ir (Fluidigm).

Flow Cytometry
Where indicated, flow cytometry was performed using either surface staining alone at room
temperature for 15 minutes or surface staining in combination with methanol permeabilized
intracellular staining at room temperature for 60 minutes before acquisition using a Fortessa X-20
(BD). Data analysis performed using Cytobank214 or FlowJo. Human antibodies used in this study:
APC CD56 (clone 5.1H11, Biolegend), Pacific Blue CD3 (clone OKT3, Biolegend), APC Cy7
CD14 (Clone HCD14, Biolegend), FITC NKG2D (clone 1D11, Biolegend), FITC CD16 (clone
3G8, BD), PE NKp44 (clone P-44-8, Biolegend), PE 2B4 (clone C1.7, Biolegend), PE-Cy7 CD19
(clone HIB19, Biolegend), APC IgM (clone MHM-88, Biolegend), APC-Cy7 HLA-DR (clone
L243, Biolegend), and Alexa Fluor 488 total PLCG2 (clone K86-1161, BD). Mouse antibodies
used in this study: BV786 CD45 (clone 30-F11, BD), BV421 NK1.1 (clone PK136, BD), BV510
IgM (clone R6-60.2, BD), FITC CD11b (clone M1/70, Biolegend), PE-Cy7 CD27 (clone LG3A10,
Biolegend), PE CD4 (clone GK1.5, Biolegend), PerCP IgD (clone 11-26c.2a, Biolegend), APC
B220 (clone RA3-6B2, BD), APC-Cy7 CD3 (clone 17A2, Biolegend), APC-R700 CD8 (clone
RPA-T8, BD), FITC CD43 (clone S11, Biolegend), PE CD24 (clone 30-F1, Biolegend), PE-Cy7
CD11b (clone M1/70, BD), PE Ly49H (clone 3D10, BD), and APC-Cy7 CD19 (clone 1D3, BD).
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ELISA
Human serum IgG and IgM levels were analyzed using commercially available ELISA kits
(Invitrogen) according to manufacturer instructions. Briefly, ELISA plates were coated with
capture antibody overnight before washing, blocking and incubation with diluted patient sera or
standard. Plates were then washed again, incubated with HRP-conjugated detection antibody,
washed again and incubated with TMB substrate solution. Solution was then stopped with 1M
phosphoric acid and absorbance was measured at 450nm.

Calcium Flux Analysis
For human samples, NK cells were enriched using RosetteSep Human NK Cell Enrichment (Stem
Cell Technologies). 1-2x106 enriched NK cells were then loaded with Indo-1 dye (Invitrogen) and
labelled with PE or FITC conjugated mouse IgG antibodies against the NK cell receptors 2B4 and
NKG2D. Kinetic measurements of calcium flux were obtained using a BD Fortessa X-20 at
baseline and then upon antibody crosslinking using anti-mouse IgG. Mouse calcium flux analysis
was similarly performed: NK cells were isolated from spleen using EasySep Mouse NK Cell
Enrichment (Stem Cell Technologies), loaded with Indo-1, labelled with APC NK1.1 followed by
crosslinking and acquisition as above. Patient B.II.4 was performed similarly except that expansion
beforehand was required due to limited patient sample and anti-NKp44 and anti-NKG2D were
used for crosslinking. NK cells were expanded as previously described215. Briefly, 106 PBMCs
from patient B.II.4 or healthy control were co-incubated with 106 irradiated (100Gy) K562mbIL15-41bbl (Kind gift from Dario Campana, National University of Singapore) for 7 days. After
7 days, cells were removed and assessed for purity. T cells (CD3+) were present at less than <1%.
100U/mL of recombinant IL-2 (Proleukin) was added to the culture and incubated for 7 more days
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with partial media exchange every 2 days. After 14 days total, NK cells expanded 10 to 15-fold
with >95% purity (CD56+CD3-) and were then used for cytotoxicity and calcium flux assays. For
murine B cell calcium flux analysis, naive B cells were gated on whole splenocytes (B220+CD27) and treated as above, with the exception of using anti-mouse IgM as the crosslinking antibody.
Human B cell calcium flux analysis was performed from PBMCs (gated as CD19+) with the
exception of using anti-human IgM as the crosslinking antibody.

Statistics
Normal internal reference ranges for human NK cell cytotoxicity and mass cytometry were
determined using 25 healthy controls; outliers were removed using ROUT (Robust regression and
Outlier removal) and the central 95th percentile was determined. Upper and lower bounds are
visualized by dashed lines. Unless normality was established after D’Agostino & Pearson omnibus
test for normality, pairwise comparisons are made using Mann-Whitney U test with Bonferroni
correction for multiple comparisons Where noted, comparisons between healthy controls and
patients are performed using age and gender matched healthy control donors. All statistics
performed using Graphpad Prism.

Molecular Dynamics, Structural Analysis, and Conservation Analysis
Structural diagrams were generated using PyMOL v2.0 (PyMOL Molecular Graphics System).
Conservation analysis of the G595 and L183 residues were generated using M-Coffee with ESPript
secondary structure analysis216-218. For molecular dynamics, 134.9µs of aggregate simulation time
of the SH2 domain (107 aa) with wild-type (69.4µs) and G595R mutant (65.5µs) sequences was
ran with GROMACS 2016.1 at 300K using the AMBER03 force field with explicit TIP3P
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solvent219-221. Salt was added to neutralize the system and create a solution concentration of 100mM
(13 Na+/14 Cl- for wild-type, 16 Na+/18 Cl- for G595R). Simulations were prepared by placing the
starting structure for each sequence in a dodecahedron box that extended 1.0Å beyond the protein
in any dimension. Each system was then energy minimized with the steepest descent algorithm
until the maximum force fell below 100 kJ/mol/nm using a step size of 0.01 nm and a cutoff
distance of 1.2 nm for the neighbor list, Coulomb interactions, and van der Waals interactions. For
production runs, all bonds were constrained with the LINCS algorithm and virtual sites were used
to allow a 4fs time step222. Cutoffs of 1.0 nm were used for the neighbor list, Coulomb interactions,
and van der Waals interactions. Before being run in production, systems were equilibrated with
position restraints for all heavy atoms for 1ns. The Verlet cutoff scheme was used for the neighbor
list. The stochastic velocity rescaling (v-rescale) thermostat was used to hold the temperature at
300 K. Conformations were stored every 10ps223. The initial structure for both simulations was a
homology model of Swiss Model threading the human PLCG2 sequence onto 4EY0, a crystal
structure of the close human paralog, PLCG1224. The human paralog was used (rather than the
murine homolog) because the crystal structure contains both nSH2 and cSH2 domains and so
provided more information about the course of the C-terminal amino acids of the nSH2 domain
than the murine homolog structure 2DX0225. A microstate decomposition was built using khybrid
clustering with a radius of 1.5Å and 5 rounds of kmedoids updates on the entire 135µs dataset
using backbone atoms (C, Cα, N, O) and Cβ (except residue 595) to produce 2314 states226. Using
the cluster centers derived in this way, the data for the wild-type and the mutant was reassigned
separately and generated separate Markov state models on this shared state space. Transition
probabilities were fit with the transpose method227. The state space had near complete coverage for
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both sequences with the wild-type sampling 2204/2315 states and the mutant sampling 2150/2315
states. The lagtime was 1.5 ns and was determined using the implied timescales test.

Section 3.3 Heterozygous PLCG2 Mutations in Functional NK Cell Disorder
Patients
We identified patients from two unrelated nonconsanguineous families with autosomal dominant
immunodeficiency, characterized by recurrent infections and reduced NK cell killing. In family A
(Figure 3.1A), patient A.I.2 is a CMV/HSV1-seronegative 52-year-old Caucasian female with a
history of arthralgias, antiphospholipid syndrome, and late-onset recurrent Staphylococcal
septicemia. Her daughter, A.II.3, is a 19-year-old female with a history of arthralgias and
autoimmunity (positive antinuclear antibody and type 1 diabetes), as well as recurrent HSV1
gingivostomatitis requiring prophylactic valacyclovir. Family B (Figure 3.1B) consists of patient
B.II.4, a 9-year-old Qatari male with a history of CMV myocarditis, as well as adenoviral hepatitis.
There was no history of immunodeficiency or autoimmunity in any other family members. Clinical
NK cell testing in both families revealed reduced NK cell K562 killing, despite intact CD107
degranulation against K562 cells and normal cytotoxic granule contents (Figure 3.1C, Table 3.1).
Flow cytometry of peripheral blood demonstrated normal NK cell percentages and absolute counts
inconsistent with classical NKD (Figure 3.1D, Table 3.1). Further clinical immunology evaluation
of immunoglobulin levels (IgM, IgG, IgA, and IgE), protective antibody titers, T cell mitogen
stimulation, and immune subpopulation analysis was also unremarkable (Table 3.1)

Patients and unaffected relatives underwent whole-exome sequencing which revealed novel
heterozygous PLCG2 missense variants. Patients A.I.2 and A.II.3 possessed heterozygous
mutations (c.1783G>A, p.G595R) in PLCG2, located in the N-terminal SH2 domain (nSH2). An
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additional healthy HSV1-seropositive 17-year-old sibling (A.II.2) with the mutation was
identified; however, her borderline-normal NK cell killing suggests incomplete penetrance, a
common feature of autosomal dominant immune syndromes228. Patient B.II.4 possessed a different
heterozygous mutation in PLCG2 (c.547C>T, p.L183F), located in the N terminus of PLCG2,
within EF-hand domains, which, along with the nearby PH domain, is responsible for membrane
localization in the phospholipase-C family149,229. Patient B.I.1 also possessed this mutation but was
not available for evaluation. The locations of these mutations and other reported PLCG2 mutations
are diagrammed in Figure 3.1E.
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Figure 1
A. Kindred A: PLCG2, c.1783G>A, p.G595R
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Figure 3.1: Familial NK Cell Deficiency Associated with Novel Heterozygous PLCG2
Mutations
(A) Pedigree of family A; affected heterozygotes are shown in black symbols while unaffected or
unevaluated heterozygotes are shown in gray or white, respectively. WT, wild-type allele. Sangersequencing chromatograms are shown for patients and unaffected relatives. Arrow denotes site of
heterozygosity. (B) Pedigree and sanger sequencing of family B is displayed as in subfigure A.
(C) NK cell killing against K562 cells is quantified after incubation for four hours at a peripheral
blood mononuclear cell (PBMC) to K562 ratio of 50:1. Upper and lower internal reference ranges
are displayed with dashed lines. See supplementary appendix for generation of reference ranges.
Each point represents a unique biologic replicate, either a separate blood draw (patients) or a
separate individual (controls). (D) Flow cytometry evaluation of NK cells (CD3- CD56+) in healthy
control (HC) versus patients A.I.2, A.II.3 and B.II.4. Percentage of NK cells in the lymphocyte
gate is displayed. Internal normal NK cell reference range, 2.8% to 15.5%. (E) The location of
variants, including previously reported PLAID (Exon 19 or 20-22 deletions) and APLAID
(S707Y) variants are displayed with the domain structure of PLCG2. PH, Pleckstrin homology;
nSH2, N-terminal Src Homology 2; cSH2, C-terminal SH2; SH3, Src Homology 3. Except where
limited by patient sample availability (B.II.4 in subfigures C and D), all data is representative of
two or more independent experiments. All error bars represent standard deviation from the mean.
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Table 3.1: Clinical Characteristics and Phenotypes of PLCG2 Haploinsufficiency Patients
Patient A.I.2
Patient A.II.3
Patient B.II.4
Mutation
G595R
G595R
L183F
Absolute Lymphocyte Count*
Normal
Normal
Normal
Absolute Neutrophil Count*
Normal
Normal
Normal
Herpesvirus Infections
None
HSV1
CMV Myocarditis
Gingivostomatitis
Bacterial Infections Recurrent Sepsis
None
None
Hepatitis, Unknown Origin
Negative
Negative
Positive
HSV1 Serology*
Negative
Positive
Negative
CMV Serology*
Negative
Positive
Positive
Antinuclear Antibody*
Positive
Positive
Negative
Other Autoimmunity Antiphospholipid
Type I Diabetes
None
Syn.
Absolute NK Cell Count*
Normal
Normal
Normal
NK Cell Cytotoxicity*
Reduced
Reduced
Reduced
NK Cell Perforin/Granzyme*
Normal
Normal
Normal
NK Cell CD107
Normal
Normal
Normal
Degranulation*
NK Cell Maturity (CD57+)
Increased
Increased
Increased
+
NKG2C NK Cells
(CMV
Negative
Negative
Seronegative)
Monocytes/DCs
Reduced
Reduced
Reduced
TFH Phenotype
TFH2>TFH1
TFH2>TFH1
TFH2>TFH1
B Cell Count*
Reduced
Reduced
Normal
Class Switched Memory B
Normal
Normal
Normal
Cells
IgA/IgG/IgM*
Normal
Normal
Normal
IgE*
Not Evaluated
Normal
Normal
Pneumococcal Antibody
Normal
Not Evaluated
Normal
Titers*
T Cell Mitogen Stimulation*
Not Evaluated
Not Evaluated
Normal
*Measured in clinical laboratory

43

Section 3.4 Mass Cytometry Reveals Monocytopenia with Normal B and NK
Cell Development
As immunodeficiencies commonly arise from aberrant immune cell development or signaling,
mass cytometry (CyTOF, Table 3.2) was employed to analyze these processes in the peripheral
blood. Consistent with clinical studies, NK cell abundance, as well as the distributions of
immunomodulatory CD56Bright and cytotoxic CD56Dim NK cells, were intact (Figure 3.2A). Family
A demonstrated reduced B cells with preserved naïve to class-switched memory B cell
percentages, suggesting a defect in B cell output but not activation (Figure 3.2B). In support of
this, serum immunoglobulins, seroconversion, and IgM-induced calcium flux were normal (Figure
3.2C-D, Table 3.1). Although T cell development and calcium flux were unperturbed (data not
shown), the distribution of T follicular-helper cells (TFH) was altered with increased TFH2 cells and
decreased TFH1 cells in both families (Figure 3.3A), a pattern seen previously in human
autoimmunity230. The abundance of monocytes and dendritic cells, but not other myeloid cells (i.e.,
granulocytes), was reduced in both families as well (Figure 3.3B, Table 3.1). Human monocyte
activation with macrophage colony stimulating factor (MCSF) is dependent on PLCG2 induced
calcium flux, possibly contributing to the observed monocytopenia and bacterial susceptibility in
patient A.1.2171.
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Table 3.2: CyTOF Panel for PBMC Subpopulation and Signaling Analysis
Antigen
CD45
CCR6
CD19
CD45RA
pPLCG2
CD4
IgD
CD11c
CD16
CD127
pSTAT5
CD123
pAKT
pSTAT1
pBtk/Itk
CD27
CXCR3
pSTAT3
pMAPKAPK2
CD14
CD80
pLCK
pJAK2
IkBa
CD45RO
pNFKB
pERK
CD8
CD25
CD3
pZAP70
IgM
HLA-DR
pSTAT4

Clone
HI30
G034E3
HIB19
HI100
K86-689.37
RPA-T4
IA6-2
Bu15
3G8
A019D5
47
6H6
D9E
58D6
24a/BTK
L128
G025H7
4/P-Stat3
27B7
M5E2
2D10.4
4/LCK-Y505
D4A8
L35A5
UCHL1
K10-895.12.50
D13.14.4E
SK1
2A3
UCHT1
17a
MHM-88
L243
38/p-Stat4

Tag
089Y
141Pr
142Nd
143Nd
144Nd
145Nd
146Nd
147Sm
148Nd
149Sm
150Nd
151Eu
152Sm
153Eu
154Sm
155Gd
156Gd
158Gd
159Tb
160Gd
161Dy
162Dy
163Dy
164Dy
165Ho
166Er
167Er
168Er
169Tm
170Er
171Yb
172Yb
173Yb
174Yb

PD-1
CD56
CD11b

EH12.2H7
NCAM16.2
ICRF44

175Lu
176Yb
209Bi
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Figure 3.2: Analysis of NK Cells and B Cells in PLCG2 Haploinsufficiency
(A) Mass cytometry was performed to quantify total (CD3-CD56+), CD56Bright and CD56Dim NK
cells in the peripheral blood of HC (healthy controls), G595R patients A.I.2, A.II.2, A.II.3 and
L183F patient B.II.4. Internal reference ranges are shown as visualized by dashed lines (see
Methods). NK cell reference range, 2.8% to 15.5%. Each patient data point represents a unique
biological replicate from a different blood draw. (B) B cells (HLADR+ CD19+) are quantified and
displayed as a percentage of PBMCs. Memory formation and class-switching is assessed by
quantification of CD27+ IgM- cells within the B cell compartment. Normal B cell reference range,
6.2% to 20.2%. Each patient data point represents a unique biological replicate from a different
blood draw. (C) ELISA quantification of serum IgG and IgM obtained from HC versus patients
A.I.2, A.II.2 and A.II.3 (pooled above). Reference ranges courtesy of Mayo Clinic; IgG 487-1,327
mg/dL and IgM 37-286 mg/dL. Error bars represent standard deviation from the mean. (D) Indo1 analysis of calcium flux in primary B cells (gated CD19+ from peripheral blood mononuclear
cells) after crosslinking with anti-IgM.
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Figure 3.3: Analysis of T Cells and Myeloid Cells in PLCG2 Haploinsufficiency
(A) Mass cytometry was performed to quantify total T cells (CD3+) and T-follicular helper cells
(TFH, CD3+ CD4+ PD-1+ CCR6-) in the peripheral blood of HC (healthy controls), G595R patients
A.I.2, A.II.2, A.II.3 and L183F patient B.II.4. Internal reference ranges are shown as visualized by
dashed lines (see Methods). Each patient data point represents a unique biological replicate from
a different blood draw. Error bars represent standard deviation. Distribution of polarized TFH cells
is graphically displayed from each patient and two HC. TFH-1 gated from CXCR3+ CCR6- TFH cells,
TFH-2 gated from CXCR3- CCR6- TFH cells, TFH-17 gated from CXCR3- CCR6+ TFH cells. (B) Myeloid
lineage cells are quantified and displayed as a percentage of PBMCs. Normal reference ranges for
all myeloid cells, 4.1% to 26.3%; classical monocytes, 1.91% to 16.4%; non-classical monocytes,
0.1% to 1.4%; pDC, 0.1% to 1.1%; mDC, 0.4% to 3.8%. Each patient data point represents a
unique biological replicate from a different blood draw. Error bars represent standard deviation
from the mean.
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Section 3.5 Hypophosphorylation of PLCG2
CyTOF analysis of NK cell signaling revealed hypophosphorylation of PLCG2 in both families
(Figure 3.4A). Family A demonstrated a reduction in the magnitude of PLCG2 phosphorylation
while

family

B

displayed

a

slower

accumulation

of

phospho-PLCG2.

PLCG2

hypophosphorylation was also confirmed by flow cytometry in patients A.I.2 and A.II.3; however,
patient A.II.2 had normal PLCG2 phosphorylation (Figure 3.5A/B) consistent with her borderlinenormal NK cell killing (Figure 3.1C). Upstream Btk/Itk, ZAP70/Syk, and Lck phosphorylation
was intact, suggesting an intrinsic defect in PLCG2 (Figures 3.4B, 3.6). MAPKAPK2, activated
by PKC downstream of PLCG2-induced DAG, was similarly hypophosphorylated (Figure 3.6)231.
Total PLCG2 protein levels in family A were analyzed to establish whether hypophosphorylation
was the result of functional inhibition or reduced protein expression. Total PLCG2 protein levels
were normal in NK cells (Figure 3.4C), as well as in all other cell types examined (Figure 3.7),
suggesting that the G595R mutation compromises function and not protein expression. Analysis
of PLCG2 protein levels in patient B.II.4 was not feasible due to limited samples. Notably, this
analysis also revealed differential PLCG2 expression between immune cell subsets, including
physiologically lower PLCG2 expression in monocytes and CD56Dim NK cells than in T cells, B
cells, and CD56Bright NK cells (Figure 3.7).
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Figure 3.4: Loss-of-Function Mutations in PLCG2 and Haploinsufficiency Cause NK Cell
Dysregulation
(A) PLCG2 phosphorylation in CD56Dim NK cells after CD16 crosslinking is quantified by CyTOF,
normalized to time 0 using an arcsinh transformation in three healthy controls (HC; two females,
one male), two G595R patients (A.II.3 and A.I.2) and one L183F patient (B.II.4). A.R.M., Arcsinh
ratio of mean. Error bars represents standard deviation from the mean. (B) Btk/Itk phosphorylation
is shown as in subfigure A. (C) Total PLCG2 levels in CD56Dim NK cells is quantified by flow
cytometry in a healthy control versus G595R patients. Isotype, Isotype control (dotted black line).
HC, healthy control (solid black line). A.II.3, G595R patient (solid red line). Patient A.I.2, G595R
patient, (dotted red line). (D) Indo-1 calcium flux analysis in G595R patient A.II.3 was assessed
in naïve enriched human CD56Dim NK cells after crosslinking with NKG2D and 2B4. Open and
closed red circles represent two unique blood samples acquired one year apart (E) Western blot
analysis for PLCG2 protein expression in HEK293T cells transfected with wild-type or mutant
FLAG-tagged PLCG2. EV, empty vector. (F) Phosphorylation of FLAG-tagged wild-type or
mutant PLCG2 after 15 minutes of pervanadate stimulation in 293T cells is quantified using
phospho-flow cytometry. EV, empty vector. Except where limited by patient sample availability
(B.II.4 in subfigures A and B), all data is representative of two or more independent experiments.
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Figure 3.5: Family A phospho-PLCG2 Flow Cytometry
(A) Briefly, patient PBMCs were labeled with APC-CD56, BV421-CD3 and unconjugated mouse
anti-CD16 monoclonal antibody and washed. Cells were rested, warmed to 37C, and goat-anti
mouse antibody was added to crosslink CD16 and stimulate PLCG2 phosphorylation. At indicated
time points, cells with fixed in formaldehyde, methanol permeabilized and stained with PEphosphoPLCG2 before flow cytometry. Representative histograms are shown in (A). Median
fluorescent intensity (MFI) of PE-phosphoPLCG2 is graphed by time in (B).
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Figure 3.6: CyTOF Analysis of CD56Dim NK Cell Signaling
PBMCs were stimulated with 50ng/mL IL-12, 500U/mL IL-2, 500U/mL IFNa, 500ng/mL LPS
and 1ug anti-mouse crosslinking antibody for CD16/CD3/IgM per 106 cells for 0, 3 or 15 minutes
before fixation. Analysis of signaling pathways was performed using mass cytometry to measure
phosphoprotein levels after stimulation in CD56Dim NK cells (gated as CD3- CD56+ CD16+).
Values normalized to time 0 using an arcsinh transformation of the mean in three healthy controls
(HC, black), two G595R patients (A.II.3 and A.I.2, red) and one L183F patient (B.II.4, blue). HC,
healthy control. A.R.M., Arcsinh ratio of mean. Error bars represents standard deviation from the
mean.
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Figure 3.7: Total PLCG2 Protein Analysis by Cell Type
Total protein levels of PLCG2 were assessed in healthy controls (black) versus G595R patients
(A.I.2, A.II.2 and A.II.3, red) by flow cytometry and intracellular staining. Cells were gated and
the mean fluorescent intensity of PLCG2 was quantified. T cells, CD3+; B cells, CD3- CD19+; NK
T Cells, CD3+ CD56+; CD56Bright NK cells, CD3- CD56++, CD16-; CD56Dim NK Cells, CD3- CD56+
CD16+; Monocytes, HLADR+ CD14+ CD16-. Error bars represent standard deviation from the
mean. Each data point represents a unique individual. Data is representative of two independent
experiments.
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Section 3.6 PLCG2 Mutations Occur in Critical Structural Motifs
Bioinformatic and structural analyses of G595 and L183 suggest that these residues are intolerant
to mutation. The G595R and L183F mutations occur at highly-conserved sites in the nSH2 domain
and N-terminus of PLCG2, respectively (Figure 3.8). Only two other individuals in ExAC are
reported to have missense variants at G595, while no missense variants in L183 have been
reported205. Although no structure exists for the PH domain, nSH2 structures from murine
PLCG2225 and human PLCG1224 facilitated analysis of the G595R mutation with molecular
dynamics (MD), which has been used to understand the structural effects of mutations
previously232,233. Simulations of wild-type and G595R sequences were analyzed by this approach
and revealed conformational disturbances in the nSH2 bD-bE loop, potentially compromising the
LAT phosphotyrosine binding site (Figure 3.8B, 3.8C). In support of the bD-bE loop being critical
in SH2 function, a structurally-analogous mutation (G60R) in the loop of SHP-2 has been
previously reported as pathogenic and this loop serves as a protein-protein interaction site in the
nSH2 of PLCG1164,234.
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Figure 3.8: Conservation of PLCG2 and Molecular Dynamics Analysis (Continued Next
Page)
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Figure 3.8: Conservation of PLCG2 and Molecular Dynamics Analysis
(A) Conservation analysis of the G595 and L183 residues was generated using M-Coffee with
ESPript secondary structure analysis216-218. (B) Molecular dynamics analysis was performed to
identify principal differences between the wild-type and G595R nSH2 domain of PLCG2 to
understand potential structural effects from the G595R mutation. Molecular dynamics simulations
of both sequences were ran and a shared state space Markov state model (MSM) was built for each
sequence. One of the outputs of each MSM is the equilibrium probability that each state in the
shared state space is occupied by each sequence. This allows direct comparison of each
microstate’s energetic favorability between sequences. Because there are more than two thousand
microstates in this model, differences were systematically identified by computing the all-to-all
Cα–Cα distances for each microstate, weighting each state by its population in the wild-type and
G595R sequences, and comparing the means of these two distributions. The two distances that the
highest positive (i.e. wild-type favored) and negative (mutant-favored) mean differences were
chosen and are displayed (left). These two distances were the P570–G594 α-carbon distance and
the L605–G594 α-carbon distance. The difference in their joint distributions across all microstates
is plotted as a 2-dimensional histogram (right). This analysis shows a clear change in the preference
for adopting the P570-near, L605-far conformation in the mutant sequence and P570-far, L605near conformation in the wild-type sequence. Green indicates site of mutation. Red, mutant
preferred state. Blue, wild-type referred state. Bars identify key Cα–Cα distances. (C) APBS235
generated electrostatics and surface map of baseline versus G595R MD simulated structures. Red
arrow depicts phosphotyrosine binding site.
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Section 3.7 Reduced NK Cell Calcium Flux
The catalytic activity of PLCG2 is initiated by phosphorylation, leading to calcium flux and
granule movement/polarization. Consistent with PLCG2 hypophosphorylation, calcium flux in
patient A.II.3 was stably reduced in CD56Dim NK cells after NKG2D and 2B4 receptor crosslinking
(Figure 3.4D). Notably, CD56Bright NK cells, which express higher levels of PLCG2 protein (figure
3.7), demonstrated normal calcium flux with NKG2D+2B4 crosslinking (3.9A). Calcium flux in
CD16-crosslinked NK cells was also normal, consistent with the ability of CD16 to signal through
both PLCG1 and PLCG2 (Figure 3.9B)236. Limited patient sample required expansion of patient
B.II.4 NK cells using K562-mbIL15-41BBL cells and IL-2 before analysis215. Patient B.II.4 NK
cells also showed partially reduced calcium flux (Figure 3.9C-D), although this expansion process
largely restored NK cell cytotoxicity.
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Figure 3.9: Additional Patient Calcium Flux Assays
(A) Indo-1 calcium flux analysis in G595R patient A.II.3 was assessed in CD56Bright NK cells (CD3CD56++CD16-) from naïve enriched human NK cells after crosslinking with NKG2D and 2B4. Red
circles (filled and empty), patient A.II.3; black filled circles, HC (healthy control); black empty
circles, isotype control. (B) Indo-1 calcium flux analysis in G595R patients A.II.3 and A.I.2 was
assessed in CD56Dim NK cells (CD3-CD56++CD16-) after crosslinking with CD16. Red circles
(filled), patient A.II.3; red circles (empty), patient A.I.2, black filled circles, HC (healthy control);
black empty circles, isotype control. (C) K562 killing assay using co-culture with expanded NK
cells at E:T ratios of 1:4, 1:2 and 1:1 for 4 hours before assessment of K562 cytotoxicity. NK cells
were expanded as previously described215. Briefly, 106 PBMCs from patient B.II.4 or healthy
control were co-incubated with 106 irradiated (100Gy) K562-mbIL15-41bbl (Kind gift from Dario
Campana, National University of Singapore) for 7 days. After 7 days, cells were removed and
assessed for purity. T cells (CD3+) were present at less than <1%. 100U/mL of recombinant IL-2
was added to the culture and incubated for 7 more days, with partial media exchange every 2 days.
After 14 days total, NK cells expanded 10 to 15-fold with >95% purity (CD56+CD3-) and were
then used for cytotoxicity and calcium flux assays. (D) Indo-1 calcium flux analysis in G595R
patients A.II.3 and A.I.2 and L183F patient B.II.4 was assessed in expanded NK cells (as in C)
after crosslinking with NKG2D and NKp44. Red circles (filled), patient A.II.3; red circles (empty),
patient A.I.2, black filled circles, HC (healthy control); blue circles, patient B.II.4
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Section 3.8 PLCG2 Variants are Expressed but Nonfunctional
To establish that G595R and L183F are loss-of-function mutations, wild-type or mutant FLAGPLCG2 was expressed in 293T cells (which do not natively express PLCG2) and analyzed for
protein expression and pervanadate-induced phosphorylation. Although both mutants were
expressed

normally

(Figure

3.4E),

FLAG-PLCG2G595R

and

FLAG-PLCG2L183F

were

hypophosphorylated compared to FLAG-PLCG2Wildtype (Figure 3.4F). Together, these data
demonstrate that the G595R and L183F mutations are loss-of-function mutations and likely
contribute to functional PLCG2 haploinsufficiency.

Section 3.9 Hypomobile Cytotoxic Granule Movement
Cytotoxic granule movement was analyzed by microscopy in NK cells conjugated to K562 target
cells (Figure 3.10A). The microtubule organizing center (MTOC) to granule (MGD) and MTOC
to synapse (MSD) distances were quantified. Both distances were increased in patient A.II.3,
indicating dysregulated cytotoxic granule movement (Figure 3.10B). Synaptic actin accumulation,
regulated independently of PLCG2, was unchanged (Figure 3.10B). In T cells, calcium flux
kinetics and DAG localization influence the path and directionality of granule movement,
respectively70,71. The observed defect in NK killing despite intact CD107 degranulation (Figure
3.10C) suggests that defects in both of these processes may lead to delayed/adirectional
degranulation. Although methods to monitor DAG are limited, the defect in MAPKAPK2
phosphorylation downstream of PKC implies that this branch of PLCG2 signaling is also
dysregulated (Figure 3.6). Additionally, K562 induced NK cell IFN-g secretion was unchanged in
either family A or B (data not shown), suggesting that NK cell cytotoxicity is the primary pathway
affected by these mutations.
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Section 3.10 Increased NK Cell Maturity and Decreased Adaptive NK Cell
Responses
CyTOF was also used to examine NK cell development and receptor expression (panel in Table
3.3). Clustering of NK cells with visual stochastic neighbor embedding (viSNE) enabled
visualization of this high-dimensional data, whereby each point represents a cell and groups
represent subpopulations which may be identified by marker expression213. Activating and
inhibitory receptor expression were comparable between patient A.II.3 and control (data not
shown); however, patient NK cell density was increased in the viSNE region corresponding to
CD57+ maturation stages 3 and 4, indicating increased NK cell maturity (Figure 3.10D). This
phenotype was also noted by flow cytometry in patient B.II.4 (data not shown). CD57+ acquisition
is typically cytokine-driven and associated with increased cytotoxicity, suggesting either
persistently-elevated cytokine levels (perhaps from increased viral burden) or a potential
compensatory mechanism to increase NK cell killing237. Additionally, a distinct subpopulation of
NKG2C+ NK cells was absent in both patient A.II.3 (Figure 3.10E) and patient B.II.4 (data not
shown). In most individuals, NKG2C+ NK cells expand during CMV infection and persist
thereafter, referred to as the adaptive NK cell response238-240. The absence of this population despite
CMV seropositivity in both patients suggests this process may be impacted.
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Figure 3.10: PLCG2 Haploinsufficiency Alters Cytotoxic Granule Mobility, NK Cell
Maturation, and the Adaptive NK Cell Response
(A) Representative immunofluorescence of cytotoxic granule microscopy upon K562 target
conjugation in healthy versus patient A.II.3 NK cells. (B) Quantification of microtubule organizing
center (MTOC) to granule distance (MGD), MTOC to synapse distance (MSD), and synaptic actin
accumulation in healthy control (HC) versus patient A.II.3. * P<0.001, Mann-Whitney U Test. (C)
CD107 Degranulation against K562 target cells is quantified by CyTOF after 1:1 incubation with
healthy control or patient A.II.3 PBMCs for 6 hours. (D) viSNE on NK cells (CD3- CD56+)
overlaid with maturity subpopulations identified by traditional bivariate gating (top) with density
visualized by contour (bottom) in both healthy control (HC) and patient A.II.3. Stage 1, NKG2ACD57-; stage 2, NKG2A+CD57-; stage 3, NKG2A+CD57+; stage 4, NKG2A-CD57+. tSNE, tdistributed stochastic neighbor embedding. (E) Similar graphical representation as in subfigure D
is shown for the adaptive NK cell response marker NKG2C. All data is representative of two or
more independent experiments using two patient blood samples drawn more than 1 year apart. All
error bars represent standard deviation from the mean.
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Table 3.3: CyTOF Panel for NK Cell Development and Function
Antigen
Clone
Tag
89 Y
CD45
HI30
Barcoding
Barcoding
Barcoding
KIR2DL4 (CD158d)
181703
141 PR
CD19
HIB19
142 Nd
KIR3DS1/L1 (CD158e1, e2)
Z27
143 Nd
CD3
UCHT1
144 Nd
KIR2DS4 (CD158i)
FES172
145 Nd
KIR2DL1/DS1 (CD158a,h)
EB6B
146 Nd
NKG2D
1D11
147 Sm
KIR2DL2/2DL3 (CD158b)
CH-L
148 Nd
CD127
A019D5
149 Sm
MIP-1a
93342
150 Nd
CD107a
151 Eu
H4A3
TNF-a
Mab11
152 Sm
CD62L
DREG-56
153 Eu
KIR2DL5 (CD158f)
UP-R1
154 Sm
CD27
L128
155 Gd
KIR3DL1 (CD158e)
DX9
156 Gd
CD137
4B4-1
158 Gd
NKG2C
134591
159 Tb
CD69
FN50
160 Gd
NKp30
P30-15
161 Dy
Ki67
B56
162 Dy
CD94
DX22
163 Er
CD16
3G8
165 Ho
NKG2A
Z199
166 Er
NKp44
P44-8
167 Dy
IFN-g
B27
168 Er
CD25
2A3
169 Tm
NKp80
239127
170 Er
GzmB
GB11
171 Yb
CD57
HCD57
172 Yb
CXCR6
K041E54
173 Yb
NKp46
195314
174 Yb
Perforin
B-D48
175 Lu
CD56
HCD56
176 Yb
CD11b
209 Bi
ICRF44
DNA
Intercalator-IR
191 /193
Cisplatin
NA
194 /195 Pt
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Section 3.11 Plcg2+/- Mice Phenocopy Human PLCG2 Haploinsufficiency
To establish that PLCG2 haploinsufficiency is sufficient to cause NKD, a mouse model of
haploinsufficiency was validated by comparing wild-type and Plcg2+/- mice. While Plcg2-/- mice
have been previously described with severe B cell and NK cell defects, defects in Plcg2+/- mice
have not been previously reported178,200. Subpopulation analysis was performed using flow
cytometry and viSNE. As expected, major perturbations were seen in Plcg2-/- mice, including
altered B cell development; however, B cell and NK cell development were intact in Plcg2+/- mice
(Figure 3.11A-B). Similar to our patients, NK cell maturation was increased in Plcg2+/- mice
(Figure 3.11C). Calcium flux analysis was performed in both B cells and NK cells. Although IgMinduced calcium flux was normal in Plcg2+/- B cells, NK1.1-induced calcium flux was attenuated
in Plcg2+/- NK cells (Figure 3.11D). Correlating with reduced calcium flux, NK cell killing of
YAC-1 and RMA-S target cells was inhibited in Plcg2+/- mice (Figure 3.11E). Similar to the
clinical findings in our patients, Plcg2+/-mice had normal degranulation despite reduced
cytotoxicity (data not shown). This combination of enhanced NK cell maturation, decreased NK
cell calcium flux, and decreased NK cell killing phenocopies our patients and demonstrates that
one-copy loss of PLCG2 is sufficient to cause functional NKD.
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Figure 3.11: Heterozygous Plcg2 Mice Phenocopy Human PLCG2 Haploinsufficiency
Analysis of mouse immune cell subpopulations in the bone marrow (A), spleen and peripheral
blood (B) of Plcg2 wild-type (+/+), heterozygous (+/-), and homozygous (-/-) littermates using
flow cytometry and displayed using viSNE clustering as in figure 3D. Color key for cell types
identified by traditional bivariate is located beneath each subfigure. tSNE, t-distributed stochastic
neighbor embedding. (C) Analysis of splenic murine NK cell maturity in wild-type littermate
control versus heterozygous Plcg2 mice using CD27 and CD11b expression. DP, double positive.
SP, single positive. Example bivariate gating of murine NK cell maturation is shown. Each point
represents a unique biologic replicate. * P<0.05, Mann Whitney U Test. (D) Indo-1 calcium flux
analysis of littermate Plcg2 +/+, +/- and -/- mice is displayed after crosslinking with anti-IgM
antibody (B cells gated from whole splenocytes) or anti-NK.1.1 antibody (NK cells enriched from
spleen). (E) NK cell killing against YAC-1 and RMA-S target cells was analyzed in littermate
wild-type control versus heterozygous Plcg2 mice using enriched splenic NK cells at NK to target
ratios of 1:10, 1:1 and 10:1. Pairwise comparisons at each time point performed using t-test, *
P<0.05, after test for normality. All data is representative of two or more independent experiments.
All error bars represent standard deviation from the mean.
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Section 3.12 G595R and L183F CRISPR Mice Recapitulate Human Disease
To conclusively link the heterozygous PLCG2 mutations to the phenotypes observed in our
patients, we generated CRISPR knock-in mice with heterozygous G595R and L183F mutations.
These mice were evaluated for immune phenotype and natural killer cell function. Similar to
patients in both families, NK cell counts were preserved (Figure 3.12A). Despite normal B cell
function, family A presented with low B cell counts which was not recapitulated in the G595R
CRISPR mice, indicating this likely represents a kindred effect and is separate from the mechanism
of disease in PLCG2 haploinsufficiency (Figure 3.12A). L183F CRISPR mice also demonstrated
normal B cell counts, and both G595R and L183F CRISPR mice had normal memory B formation
(Figure 3.12A). NK cell function was tested by examination of NK cell cytotoxicity and calcium
flux. Similar to our human patients and haploinsufficient Plcg2 mice, G595R and L183F CRISPR
mice had decreased NK1.1-induced calcium flux (Figure 3.12B) and correspondingly low NK cell
cytotoxicity against YAC-1 target cells (Figure 3.12C). Together, these data demonstrate the
G595R and L183F mutations are loss-of-function mutations resulting in functional PLCG2
haploinsufficiency and NK cell functional defects without perturbance of B cell function.
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Figure 3.12: Plcg2 G595R and L183F CRISPR Mice Demonstrate Normal B Cell
Development and Perturbed NK Cell Function
(A) Analysis of NK cells, B cells, and memory B cells, in the peripheral blood from heterozygous
G595R knock-in, L183F knock- in or wild-type littermate controls using flow cytometry. Data
points represent unique biological replicates. (B) Indo-1 calcium flux analysis G595R knock-in,
L183F knock- in or wild-type littermate controls is displayed after crosslinking with anti-NK.1.1
antibody (NK cells enriched from spleen). (C) NK cell killing against YAC-1 target cells was
analyzed in G595R knock-in, L183F knock- in or wild-type littermate controls at a NK to target
ratio of 10:1. Pairwise comparisons were performed using t-test, * P<0.05, after test for normality.
Data points represent technical replicates. All data is representative of two or more independent
experiments. All error bars represent standard deviation from the mean.
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Section 3.13 Discussion
The heterozygous loss-of-function mutations presented herein result in PLCG2 haploinsufficiency,
NK cell dysfunction, and herpesvirus infections. Despite the role of PLCG2 in B cells, these cells
are functionally intact in PLCG2 haploinsufficiency. Based on the differential regulation of
PLCG2 expression among lymphocytes, we propose a threshold model wherein cell types with
homeostatically low levels of PLCG2 (i.e. CD56Dim NK cells) are uniquely susceptible to further
reductions in PLCG2 function. As a result, most lymphocytes are likely shielded from
haploinsufficiency by virtue of their high PLCG2 expression or use of alternative pathways (i.e.
PLCG1 in T cells). This model also suggests that PLCG2 may serve as a rate-limiting checkpoint
against erroneous cytotoxicity in NK cells, requiring strong PLCG2 activation for accurate and
directional degranulation. Extrapolating this model further, monocytopenia was also observed in
all patients, and monocytes express the lowest levels of PLCG2 of all cell types examined. While
the role of monocytopenia to the observed clinical phenotypes is not clear, this may also contribute
to certain features of disease, including herpesvirus and bacterial susceptibility.

Despite a number of similarities (Table S1), family A and B each possess unique features as well.
Notably, B cell output was reduced in family A (including A.II.2), but not family B. This is likely
a result from other genetic background effects, as B cell development was unaffected in G595R
CRISPR knock-in mice. Families A and B also differed in the nature of their phosphorylation
defect. Family A had reduced magnitude of PLCG2 phosphorylation while family B displayed a
slower accumulation of phospho-PLCG2. An analysis of each domain’s function provides insight
into this difference. The L183F mutation in family B occurs nears the PH and EF-hand domains,
which bind PIP3 and PIP2 (respectively) at the immunologic synapse and facilitate localization of
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PLCG2 to the membrane145. Upon reaching the membrane, the nSH2 (affected by G595R in family
A) binds to phosphorylated LAT, enabling assembly of the NK cell signalosome and interaction
of PLCG2 with its kinase (Btk/Itk)73,241. Therefore, PLCG2 with diminished membrane localization
would be capable of normal signalosome interaction, but diffusion-limited and kinetically altered.
In contrast, PLCG2 lacking a functional nSH2 domain would be blocked from signalosome
interaction and phosphorylation altogether, reducing the magnitude of calcium flux. This
hypothesis is consistent with the patterns observed in our patients and suggests that PLCG2 lossof-function mutations may have domain-specific phenotypes. Nonetheless, future studies are
needed to further delineate the exact mechanisms by which these mutations diminish PLCG2
function.

Pathogenic variants are commonly modifiable by both genetic and environmental factors. Genetic
epistasis likely plays a role in the incomplete penetrance and variable expressivity observed in
many autosomal dominant syndromes228. Immunologic context, such as the cytokine environment,
may also modulate cellular and clinical phenotypes. For example, IL-2 incubation partially
reverses NK cell killing defects in STX11-deficient patients242, reminiscent of the restoration of
patient NK cell killing after IL-15/IL-2 cytokine exposure herein (Figure 3.9C). The use of
collateral immunologic pathways may also alter phenotypes. For example, the versatile use of
either PLCG1 or PLCG2 by some NK cell receptors (i.e., CD16) may allow compensatory
signaling through these pathways. Moreover, the variable nature of the adaptive immune response
may compensate for innate defects to different degrees. A combination of these likely contributes
to the phenotypic differences and incomplete penetrance seen in PLCG2 haploinsufficiency. This
manipulability may also present an opportunity to therapeutically modify defects, for example with
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modulation of IL-15 signaling using ALT-803, an investigational drug previously shown to rectify
NK cell cytotoxicity defects in vivo and aid CMV clearance in humans243.

Whereas PLAID and APLAID represent the autosomal dominant manifestations of dominantnegative and gain-of-function mutations, the present patients illustrate haploinsufficiency and
expand the spectrum of PLCG2-related disease. A fourth possibility, autosomal recessive loss-offunction, remains either undiscovered or is incompatible with life. While these three syndromes
may be mechanistically distinct, there remains unexplained overlap (i.e. autoimmunity) that merits
further investigation. Nonetheless, PLCG2 haploinsufficiency results in clinical phenotypes
distinct from PLAID/APLAID and requires a different diagnostic and therapeutic approach.

At present, the lack of a clear etiology complicates the management of many patients with
unusually severe and/or recurrent herpesvirus infections. This study highlights a potential role for
PLCG2 mutations in these patients, provides insight into the regulation of human NK cell
cytotoxicity, and unifies PLCG2-associated disease along a clinical spectrum that now includes
PLAID, APLAID, and PLCG2 haploinsufficiency. Unlike PLAID and APLAID which require
deletions or mutations at specific locations, loss-of-function mutations could plausibly occur in
many domains beyond the SH2 and PH domains, including the catalytic, SH3 and C2 domains. Of
the 60,000 healthy exomes in ExAC, only 402 of 1265 residues in PLCG2 have been reported with
missense variants205. This evolutionary pressure against mutations in PLCG2 implicates a number
of residues where variants may disrupt PLCG2 function. As a result, heterozygous PLCG2
mutations should be considered in the differential diagnosis of patients with a number of
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presentations beyond cold urticaria, antibody deficiency, and autoinflammation, including but not
limited to NK cell immunodeficiency and herpesvirus infections.
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Chapter 4: The Spectrum of PLCG2-related
Disease
PLCG2 is closely related to the ubiquitously expressed PLCG1; however, while PLCG1 and
PLCG2 are redundant in many cell types including T cells, PLCG2 is non-redundant in B cells and
NK cells, among others. As such, Plcg2-/- mice exhibit abnormal B cell development and function,
as well as reduced NK cell cytotoxicity177-179. The role of PLCG2 in other cell types is everexpanding, with new roles in neutrophils201, platelets173, macrophages170, and osteoclasts244 being
uncovered.

N-ethyl-N-nitrosourea (ENU) mouse models have also been informative about the potential
spectrum of disease due to genetic alterations in Plcg2. The Ali5 and Ali14 mouse, heterozygous
for gain-of-function mutations at D993G and Y495C, respectively, develop spontaneous and
dominantly inherited autoinflammation resulting in cutaneous and joint inflammation142,181,245.
Contrastingly, the Queen mouse, with a point mutation at I346R in the catalytic domain, exhibits
only defects in B cell antibody responses246.

Three syndromes have been reported due to human mutations in PLCG2: PLAID, APLAID, and
more recently, PLCG2 Haploinsufficiency. Each syndrome exhibits unique clinical manifestations
that underscore the diverse spectrum of disease phenotypes possible with PLCG2 mutations.
PLAID (PLCγ2-associated antibody deficiency and immune dysregulation) was first reported in
patients with familial cold urticaria188. Linkage analysis revealed exonic deletions in these patients,
either deletions of exon 19 or exons 20-22, deleting portions of the C-terminal SH2 and SH3
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domains of PLCG2. These patients, without exception, present with cold urticaria, but also present
with varying degrees of antibody deficiency due to decreased B cell class switching (75% of
patients), antinuclear antibodies (62%), allergic disease (56%), and recurrent sinopulmonary
infections (44%). Some patients also develop granulomatous dermatitis, as well as autoimmune
disorders including autoimmune thyroiditis and vitiligo189. The molecular mechanism underlying
PLAID is unique in its temperature-sensitive nature. At physiologic temperatures, deletion of the
normally autoinhibitory C-terminal SH2 domain leads to dominant-negative dysfunction in
signalosome assembly, resulting in a loss-of-function phenotype in most cell types and thus B cell
immunodeficiency159.

However,

at

sub-physiologic

temperatures,

dysfunction

of

the

autoinhibitory domain leads to gain-of-function activity, resulting most noticeably in cold-induced
mast cell degranulation and cold urticaria. The treatment of these patients is mostly supportive,
including the avoidance of evaporative cooling (i.e. when getting out of the shower or pool) and
intravenous immunoglobulin to treat antibody deficiencies as they arise; however, future use of
PLCG2 inhibitors could be therapeutic in these patients189.

While PLAID represents a complex dominant-negative loss-of-function and temperature-sensitive
gain-of-function phenotype, APLAID (autoinflammation and PLCγ2-associated antibody
deficiency and immune dysregulation) was discovered in patients with bonafide heterozygous
gain-of-function mutations191,192. The clinical phenotypes of these patients are extensive, with
multiple autoinflammatory features affecting several organ systems. Granulomatous skin lesions,
enterocolitis, uveitis, arthralgias, interstitial lung disease, and mild humoral immunodeficiencies
may all be present in these patients, reported with gain-of-function mutations at either S707Y in
the C-terminal SH2 or L848P in the split PH domain. These mutations, unlike PLAID, do not lead
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to cold urticaria or autoantibodies (despite the amount of autoinflammation present). These
patients respond to high-dose corticosteroids, but symptoms are largely refractory to nonsteroidal
anti-inflammatory drugs, TNF inhibitors, or IL-1 inhibitors.

Most recently, PLCG2 Haploinsufficiency has been described in patients with heterozygous lossof-function mutations. Unlike PLAID, these mutations are not dominant-negative or temperature
sensitive, affecting a more restricted cellular repertoire that includes NK cells, but not B cells.
These patients primarily present with NK cell dysfunction, monocytopenia, and severe or recurrent
Herpesvirus infections, including Herpes Simplex Virus 1 (HSV1) and Cytomegalovirus (CMV)
infections that require antiviral prophylaxis. The mutations in these patients occur in distinct
domains, G595R in the N-terminal SH2 domain, or L183F in the EF hand domain, likely
compromising the ability of PLCG2 to associate with the signalosome or target properly to the
membrane. Unlike PLAID or APLAID, the humoral responses in these patients is intact. However,
several other features such as bacterial infections, autoantibody formation, and arthralgias are
shared with the other syndromes affecting PLCG2. The mechanism of this overlap is not clear;
however impaired monocyte function and dysfunctional follicular T cell regulation by NK cells
may be responsible for certain aspects of all three syndromes.

The differing phenotypes among these three syndromes (summarized in table 4.1) serves as an
interesting study in how gene dosage and domain-specific mutations may impact phenotype in a
genetic disease. As PLCG2 is expressed at different levels among hematopoietic cells, the relative
susceptibility of a given cell type to either a loss-of-function or gain-of-function mutation is
dictated by the physiologic level of PLCG2 at baseline. In cell types with higher expression of
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PLCG2, such as neutrophils and B cells, gain-of-function mutations impact function more so than
in cell types with lower physiologic expression of PLCG2, such as NK cells. Contrastingly, lossof-function mutations largely spare cell types with higher baseline PLCG2 expression as is the
case in PLCG2 haploinsufficiency which appears not to impact higher PLCG2 expressing cells
such as B cells but renders lower PLCG2 expressing NK cells susceptible to dysfunction. The
unique dominant-negative loss-of-function and gain-of-function mechanism of PLAID affects a
variety of cell types independent of cellular PLCG2 expression as the dominant-negative nature of
the deletion renders all copies of PLCG2 inert even in B cells that express high levels of PLCG2.
Indeed, the phenotypes of each disease can be well predicted based on the expression of PLCG2
in a given cell type (see figure 4.1).

PLCG2 is a key signaling molecule in a variety of hematopoietic cells and thus, not surprisingly,
the dysregulation of this enzyme in human patients leads to a variety of clinical phenotypes. Each
syndrome presents with both unique and shared clinical features that may be explained by the role
and differential expression level of PLCG2 in immune cells. As the clinical presentation may range
dramatically from cold urticaria to severe autoinflammation to viral immunodeficiency, it is
critical for the clinician to recognize mutations in PLCG2 as potentially pathogenic variants
underlying disease in a diverse set of patients.

73

Table 4.1: Clinical Characteristics of PLAID, APLAID and PLCG2 Haploinsufficiency
PLCG2
PLAID188
APLAID191
Haploinsufficiency
Mutation
cSH2 Deletions
S707Y
G595R, L183F
Dominant-negative or
Loss-of-function
Mechanism of Disease
Gain-of-function
Gain-of-function*
(haploinsufficiency)
Cold Urticaria
+
Inflammatory Skin Lesions
+
+
and Cutaneous Granulomas
Allergic Disease
+
Arthralgias
+
+
Autoantibodies/Autoimmunity
+
+
Bacterial Susceptibility
+
+
+
Herpesvirus Susceptibility
+
NK Cell Count
Decreased
Normal
Normal
NK Cell Killing
NR
NR
Decreased
NK Cell Degranulation
Decreased
NR
Normal
NK Cell Calcium Influx
Decreased
NR
Decreased
B Cell Count
Decreased
NR
Normal/Decreased
B Cell Class Switching
Decreased
Decreased
Normal
IgG/IgA/IgM levels
Decreased
Normal
Normal
B Cell Calcium Influx
Decreased/Increased†
Increased
Normal
†
Mast Cell Degranulation
Normal/Increased
NR
NR
Table 4.1 Legend
NR, not reported. PLAID, PLCG2-associated Antibody Deficiency and Immune Dysregulation.
APLAID, Autoinflammation & PLCG2-associated Antibody Deficiency and Immune
Dysregulation. *Temperature dependent mechanism. †At 37°C, B cell calcium is inhibited while
mast cell degranulation is unchanged. At sub-physiologic temperatures B cell calcium and mast
cell degranulation are increased.
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Figure 4.1: Human Disorders of PLCG2
The proposed cellular mechanism behind PLAID (PLCγ2-associated antibody deficiency and
immune dysregulation), APLAID (autoinflammation and PLCγ2-associated antibody deficiency
and immune dysregulation), and PLCG2 Haploinsufficiency are summarized.
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